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Abstract
Background—Extracellular matrix (ECM) remodeling contributes to in-stent restenosis and 
thrombosis. Despite its important clinical implications little is known about ECM changes post-
stent implantation. 
Methods—Bare-metal (BMS) and drug-eluting stents (DES) were implanted in pig coronary 
arteries with an overstretch under optical coherence tomography guidance. Stented segments 
were harvested 1, 3, 7, 14 and 28 days post-stenting for proteomics analysis of the media and 
neointima.
Results—A total of 151 ECM and ECM-associated proteins were identified by mass 
spectrometry. After stent implantation, proteins involved in regulating calcification were 
upregulated in the neointima of DES. The earliest changes in the media were proteins involved in 
inflammation and thrombosis, followed by changes in regulatory ECM proteins. By day 28, 
basement membrane proteins were reduced in DES compared with BMS. In contrast, the large 
aggregating proteoglycan aggrecan was increased. Aggrecanases of the ADAMTS (a disintegrin 
and metalloproteinase with thrombospondin motifs) family contribute to the catabolism of 
vascular proteoglycans. An increase in ADAMTS-specific aggrecan fragments was accompanied 
by a notable shift from ADAMTS1 and ADAMTS5 to ADAMTS4 gene expression after stent 
implantation. Immunostaining in human stented coronary arteries confirmed the presence of 
aggrecan and aggrecan fragments, in particular at the contacts of the stent struts with the artery. 
Further investigation of aggrecan presence in the human vasculature revealed that aggrecan and 
aggrecan cleavage were more abundant in human arteries compared to veins. Also, aggrecan 
synthesis was induced upon grafting a vein into the arterial circulation, suggesting an important 
role for aggrecan in vascular plasticity. Finally, lack of ADAMTS-5 activity in mice resulted in 
an accumulation of aggrecan and a dilation of the thoracic aorta, confirming that aggrecanase 
activity regulates aggrecan abundance in the arterial wall and contributes to vascular remodeling.
Conclusions—Significant differences were identified by proteomics in the ECM of coronary 
arteries after BMS and DES implantation, most notably an upregulation of aggrecan, a major 
ECM component of cartilaginous tissues that confers resistance to compression. The 
accumulation of aggrecan coincided with a shift in ADAMTS gene expression. This study 
provides the first evidence implicating aggrecan and aggrecanases in the vascular injury response 
after stenting.
Key Words: extracellular matrix; mass spectrometry; stent; neointima; coronary artery disease
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Clinical Perspective
What is new?
x Despite continuous development in stent technology, in-stent restenosis and 
neoatherosclerosis remains a considerable cause of stent failure. 
x A proteomics approach to identify extracellular matrix protein changes in response to 
bare-metal stent and drug-eluting stent insertion revealed differential expression of 
aggrecan, a proteoglycan that is usually associated with articular cartilage.
x Aggrecanase activity is part of the vascular injury response post-stenting.
What are the clinical implications?
x Aggrecan cleavage is the hallmark of cartilage degeneration in a number of degenerative 
diseases including rheumatoid arthritis and osteoarthritis. 
x Aggrecanase activity might offer new drug targets to alter extracellular matrix 
remodeling in the vasculature.
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Percutaneous coronary intervention with stent implantation has become the most widely used 
treatment for coronary artery disease. Use of stents reduced the impact of acute elastic recoil and 
occlusive dissection on restenosis observed with balloon angioplasty.1, 2 However, stent 
implantation induced an excessive healing process, which in case of bare-metal stents (BMS) led 
to neointimal hyperplasia and in-stent restenosis. The introduction of drug-eluting stents (DES) 
reduced the burden of in-stent restenosis and repeat revascularization.3, 4 On the other hand, DES 
implantation delays vessel re-endothelialization due to the non-selective nature of these drugs, 
resulting in an increased risk of late and very late stent thrombosis requiring prolonged dual 
antiplatelet therapy.5 Late stent thrombosis has also been associated with the inflammation and 
hypersensitivity reactions to the non-biocompatible polymer coatings on DES.6 Moreover, in the 
long term neoatherosclerosis is likely to occur earlier in DES than in BMS.7 Second-generation 
DES with durable biocompatible polymers are current standard of care because of their excellent 
efficacy and safety. A further development in stent technology uses biodegradable polymers as
well as fully biodegradable non-metallic scaffolds.8, 9
However, despite continuous development in technology, in-stent restenosis remains a 
considerable cause of stent failure.10 Neointimal hyperplasia involves the interaction between 
inflammatory cells, platelets, smooth muscle cells (SMC) and endothelial cells (EC) leading to 
progressive obliteration of the vascular lumen.11 Platelet activation and inflammation as an early 
response to stent deployment result in increased SMC migration, proliferation and extracellular 
matrix (ECM) production. Yet, little is known about changes in ECM composition upon vascular 
stent injury, even though more than 50% of the neointimal hyperplasia consists of ECM 
proteins.12 Our current knowledge of ECM remodeling after stent injury and during neointima 
formation is mainly based on histopathological analysis investigating the role of only few 
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selected ECM proteins.12, 13 In comparison, proteomics is a powerful underpinning technology to 
profile not just individual ECM proteins by antibody staining but characterize the different stages 
of ECM remodeling by liquid chromatography tandem mass spectrometry (LC-MS/MS). 
Therefore, the aim of the present study was to use proteomics to characterize ECM 
remodeling in porcine coronary arteries stented with BMS and DES. Pigs are well suited for 
these studies, since the stages of the healing process closely resemble the human disease, but the 
time course of neointimal hyperplasia formation is notably shorter.14, 15
Methods
An expanded methods section is available in the online-only Data Supplement at
http://circ.ahajournals.org/. The data, analytic methods, and study materials will not be made 
available to other researchers for purposes of reproducing the results or replicating the procedure
due to the limited amount of tissues. The proteomics data, however, are deposited in PRIDE
(https://www.ebi.ac.uk/pride/archive/) with the dataset identifier PXD005726 and 
10.6019/PXD005726.
Porcine Model of Stent Injury
All porcine animal procedures were approved by the local ethical committee for animal 
experiments, Institute of Pharmacology Polish Academy of Science, Cracow, Poland. 12 healthy 
male and female domestic pigs (3-4 months old, 28-48kg) underwent percutaneous coronary 
intervention through transfemoral access. To prevent the risk of in-stent thrombosis pigs received 
a loading dose of aspirin and clopidogrel orally 24h before intervention and remained on this 
dual antiplatelet therapy until termination. The coronary arteries of each animal (LAD, LCX and 
RCA) were either stented with a BMS (MULTI-LINK cobalt-chromium stent, Abbott Vascular, 
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US) or DES based on the same cobalt-chromium platform (XIENCE PRO everolimus-eluting 
stent with durable fluoropolymer, Abbott Vascular, US) or had balloon angioplasty alone (BA). 
Full strut expansion was achieved for each deployed stent. Quantitative coronary angiography 
and optical coherence tomography (OCT) were performed 1, 3, 7, 14 or 28 days post-stent 
implantation, followed by harvesting of the coronary arteries. The neointima lesions that had 
developed in stented arteries at day 28 were dissected from the media and analyzed separately. In 
total, 31 samples were analyzed by LC-MS/MS for the media (n=3 BMS and n=3 DES at each 
time-point 1, 3, 7 and 28 days; n=4 BA early [day1-day3] and n=3 BA late [day 14 - day28]). 
For the neointima, a total of 14 samples were analyzed (n=7 BMS, n=7 DES at 28 days). Six 
coronary arteries of 4.5 months old healthy pigs were harvested as unstented controls.
ECM Extraction 
The ECM proteins for the media were extracted in a three-step manner with a method previously 
developed in our laboratory for the enrichment of ECM proteins.16 In brief, newly synthesized, 
loosely bound ECM proteins were extracted in 0.5M NaCl (1.5h), followed by decellularization
of the tissue in 0.08% SDS (1.5h) to remove intracellular material. Eventually the tissue pieces 
were incubated in 4M guanidine HCl buffer (GuHCl, 48h) by vigorous shaking at room 
temperature to extract the strongly bound ECM components. The buffers contained protease 
inhibitors and EDTA to prevent ECM protein degradation by proteases. Proteins of the thinner 
neointimal tissues were extracted only in GuHCl buffer for 48h. 
Proteomics Analysis in Porcine Tissue
After deglycosylation, proteins were subjected to in-solution digestion and analyzed by liquid 
chromatography tandem-mass spectrometry (LC-MS/MS). 15μg of deglycosylated proteins of 
the GuHCl extracts were denatured with 6M urea and 2M thiourea, reduced with 10mM DDT 
 by guest on O
ctober 31, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.116.023381
7
and alkylated with 50mM iodoacetamide, followed by acetone precipitation of the proteins and 
tryptic digestion overnight. Subsequently, peptides were cleaned up using C18 spin plates and 
separated on a nanoflow high-performance LC column (Acclaim, ThermoFisher) using an 
UltiMate 3000 RSLCnano LC system (ThermoFisher) interfaced to a Q Exactive Plus Orbitrap 
mass spectrometer (ThermoFisher). MS/MS analysis was performed on the 15 most abundant 
ions in each full MS scan with dynamic exclusion enabled.17 Raw files were searched using 
Proteome Discoverer 1.4 against a custom-made database, containing porcine ECM proteins with 
a human proteome background (UniProtKB/Swiss-Prot Release 2014_06, 20220 protein entries) 
using Mascot. All data were exported to mzIdentML format using Scaffold and deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository.
Immunohistochemistry in Human Specimen
Human samples were collected under the Bristol Coronary Biobank ethical approval 
08/H0107/48. The artery including stent was fixed in 10% formalin, then the stent was removed 
and the tissues were paraffin embedded and sectioned at 3μm thickness using a microtome. For 
immunostaining deparaffinised and rehydrated samples were incubated in 0.3% H2O2 for 10min 
to block endogenous peroxidases, then incubated in boiling water bath in preheated 10mM 
sodium citrate buffer (pH6.0) for antigen retrieval. Sections were blocked with either 20% goat 
(for rabbit primary) or rabbit serum (for goat primary) in PBS for 1h and subsequently incubated 
with primary antibody or matched rabbit IgG control (5μg/ml) in 1% goat or rabbit serum and 
incubated at 4°C overnight. Primary antibodies were used to aggrecan (1:400; Abcam, ab36861), 
the NITEGE neoepitope of aggrecan (1:400; Thermo, AF-PA11746), HPLN1 (1:200; Abcam, 
ab103455), the DPEAAE neoepitope of versican (1:400; Abcam, ab19345), MGP (1:100; 
Abcam, ab86233) and SPP24 (1:50; sc-169408, Santa Cruz). Biotinylated goat anti-rabbit 
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(1:250; Sigma, B7389) or rabbit anti-goat (1:250; Dako, E0466) secondary antibodies were 
applied for 1 h, followed by wash steps and Extravidin-HRP (1:250; Sigma, E2886) incubation. 
DAB solution (Vector) for 10min was used for detection. Sections were washed in dH2O, 
counterstained for 15 sec in modified Harris Haematoxylin, dehydrated and mounted in DPX. 
Histological slides were digitally scanned using a digital scanning system (LEICA SCN400F) to 
provide a high resolution digital image.
Statistical Analysis
Data are shown as average (Av) ± standard error of the mean (SEM). MS data were quantified 
using ion intensities (total ion current, TIC). IBM® SPSS® statistics software (version 22) and 
Microsoft® Excel® (version 15.20) were used for statistical calculations, GraphPad Prism® 
(version 6.0e) and Microsoft® Excel® (version 15.20) for data illustration. For optical coherence 
tomography (OCT) analysis, 2-way analysis of variance (ANOVA) was applied to assess 
neointimal volume, minimal lumen area and strut coverage between BMS and DES at different 
time points. 1-way ANOVA was applied for changes in protein abundance and gene expression 
in BMS and DES at different time-points. Unpaired Student’s t-test with unequal variance was 
applied for proteomics differences between neointimal BMS and DES, BA early and late, for 
differences between BMS and DES at each time point (visualized as a volcano plot for changes 
at day 28) as well as the comparison between BMS or DES day 28 vs. BA late. Unpaired, two-
tailed Student’s t-test with unequal variance was also used for the proteomics data in mice, as 
well as comparisons on murine aortic diameter, blood pressure and cardiac output.
MultiExperiment Viewer software (MeV, version v4.9) was applied using Pearson correlation 
for protein clustering. For gene expression analysis of porcine tissue t-tests were applied for 
differences between BMS and DES and regression analysis for changes at different time-points
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(P value for trend). Student’s t-test with unequal variance was used for densitometry 
quantification of immunoblots. Correction for multiple comparisons was performed using the 
Benjamini-Hochberg procedure18, controlling the false discovery rate (FDR). Uncorrected P
values and FDR are presented in the tables. P values < 0.05 were considered significant. A FDR
threshold of 10% was applied.
Results
Proteomics Analysis of a Porcine Model of Stent Injury
BMS or DES were implanted in porcine coronary arteries. Coronary arteries subjected to balloon 
angioplasty alone without stent deployment served as controls (Figure 1A). At five time points 
1, 3, 7, 14 and 28 days post-stent implantation OCT was performed (Figure 1B). The OCT 
analysis revealed that at 14 days post-stent implantation neointimal volume was higher in BMS 
compared to DES (P=0.025) with no significant difference at day 28. The minimal lumen area 
and the stent strut coverage were not different for BMS and DES during the 28 days follow-up.
Time points without significant differences were chosen for proteomic analysis to identify 
differences in the ECM composition. In total, 45 samples were analyzed by proteomics 
(Supplemental Figure 1). Characteristics of all samples are summarized in Supplemental Table 1.
A three-step extraction method as previously described was used to sequentially extract 
the ECM proteins of the vascular media.16 28 days post-stent implantation, a neointima had 
evolved on top of the stent struts regardless of the stent-type. The neointima was separated from 
the media before proteomics analyses. Following deglycosylation and tryptic digestion, 
proteomics analysis was performed of the neointima and the media by LC-MS/MS (Figure 1C).
Duplicate measurements performed on the neointima samples showed good reproducibility for 
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spectral counts and sequence coverage as well as number of identified peptides (Supplemental
Figure 2). 
To improve the identification of ECM proteins upon MS, a custom-made pig ECM 
protein database was generated for database search containing a comprehensive porcine 
sequence list of previously published ECM proteins (Supplemental Figure 3). A total of 151 
unique ECM proteins were identified overall in the neointima and the media with a minimum of 
2 high-confidence peptides (Supplemental Figure 4, Supplemental Table 2-4). Proteins only 
identified in the media (n=11) or neointima (n=26) are marked with an asterisk. 
Comparison of the neointima of DES and BMS
Compared to BMS, the neointima of arteries with DES implantation contained less structural 
constituents of the ECM like collagen type I, III, V as well as regulatory ECM proteins such as 
biglycan, lumican, fibromodulin or periostin (Figure 2A); in contrast, proteins involved in the 
regulation of calcification such as matrix Gla protein (MGP), secreted phosphoprotein 24
(SPP24) and bone morphogenetic protein 1 (BMP1) were increased (Figure 2B). Interestingly, 
proteomics also uncovered the presence of chondroadherin in coronary arteries with DES 
(Figure 2B). This small leucine-rich proteoglycan (SLRP) has not been previously reported in 
the vasculature. Next, we tested whether everolimus treatment had an effect on calcification of 
human aortic SMCs in culture using the o-Cresolphthalein assay (Figure 2C). Everolimus was 
coated on the DES used in porcine coronary arteries. Indeed, an inhibition of calcification was 
observed upon everolimus treatment. Immunohistochemistry localised both MGP and SPP24 in 
human coronary arteries with atherosclerotic plaques with and without stent implantation 
(Figure 2D).  
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ECM Changes in the Media Post-stenting
ECM remodelling in response to stent implantation was compared at four different time points
(Figure 3A-B). Coronary arteries subject to balloon angioplasty without stent implantation 
served as controls (Figure 3C). At an early stage, proteins regulating hemostasis (e.g. 
plasminogen, fibrinogen, antithrombin-III) and inflammation (e.g. pentraxin-related protein 
PTX3, prophenin and tritrpticin precursor) were increased, alongside apolipoproteins found on 
VLDL particles, including apoC-III, apoE, and apoR.19 Proteins with a late response included 
large aggregating proteoglycans (aggrecan, versican), fibrillar collagens (e.g. type I, III and V), 
SLRPs (decorin, biglycan, fibromodulin, podocan, asporin) and matricellular proteins (e.g. 
periostin, tenascin, SPARC). Generally, fewer proteins changed in the BA group than in stented 
arteries and more pronounced changes were seen in DES compared to BMS (Figure 3D;
Supplemental Table 5). Differences in the ECM between DES and BMS became most obvious at 
day 28 (Figure 3E) and were not revealed by OCT imaging. Thus, DES not only affect cell 
proliferation but also the composition of the ECM. 
Comparison of the Media of DES and BMS
At day 28, the anti-proliferative effects of DES compared to BMS were reflected in a lower 
abundance of basement membrane proteins such as collagen alpha-2 IV (CO4A2), collagen 
alpha-1 XVIII (COIA1), as well as laminin beta-1 (LAMB1), laminin beta-2 (LAMB2) and 
laminin gamma-1 (LAMC1) (Figure 4A; Supplemental Table 6). In contrast, the large 
aggregating proteoglycan aggrecan (PGCA) was upregulated after stenting, particularly in DES 
(Figure 4B). Aggrecan is the major proteoglycan in the articular cartilage and interacts with 
hyaluronic acid. Its rise mirrored the increase of versican, the major large aggregating 
proteoglycan in the vasculature (Figure 4B). Aggregates of aggrecan and versican with 
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hyaluronic acid are stabilized by hyaluronan and proteoglycan link protein 1 (HPLN1). HPLN1 
was reduced in the media of DES compared to BMS (Figure 4B).
Stent-induced Changes in Aggrecan and Aggrecanase Expression
Due to its unknown function in the vasculature, aggrecan was selected for further validation. For 
comparison, we used versican as a structurally and functionally related large proteoglycan. A rise 
of aggrecan and versican expression after stenting was confirmed at the transcript level (Figure 
4C). Consistent with the proteomics findings, there was no equivalent increase in the gene 
expression of hyaluronan and proteoglycan link protein 1 (HAPLN1). 
Besides gene expression, protein degradation determines the abundance of ECM proteins 
in the vessel wall. Aggrecanases are members of the ADAMTS (a disintegrin and 
metalloprotease with thrombospondin motifs) family that can cleave aggrecan and other large 
aggregating proteoglycans like versican. Thus, we used neoepitope antibodies that only 
recognize aggrecan and versican upon cleavage by members of the ADAMTS family, but not by 
other proteases like matrix metalloproteinases. For aggrecan, we probed for the signature 
cleavage at NITEGE373-ARGTV in the interglobular domain at the N-terminus, whereas versican 
fragments were detected by the DPEAAE neoepitope (Figure 5A). The rise in aggrecan was 
accompanied by increased detectability of the NITEGE neoepitope in DES (Figure 5B,
Supplemental Figure 5). After an initial loss at day 3, a similar increase of the ADAMTS-
generated DPEAAE containing versican fragments was observed (Figure 5B, Supplemental
Figure 5). At day 28, both were more pronounced in DES compared to BMS (Figure 5C,
Supplemental Figure 6). These findings demonstrate, for the first time, the contribution of 
aggrecanases to vascular remodeling upon stent implantation.
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As the neoepitope antibodies do not distinguish between the activities of the different 
aggrecanases and may reflect differences in substrate availability rather than changes in 
aggrecanolytic activity, we investigated the gene expression of the three main ADAMTS 
enzymes that cleave large aggregating proteoglycans: ADAMTS-1, -4 and -5. Upon stenting, 
there was a notable reduction in ADAMTS1 and 5 gene expression, followed by an increase in 
ADAMTS4 (Figure 5D). ADAMTS1 showed the highest expression levels in porcine coronary 
arteries (Figure 5E).
Aggrecan and Aggrecanase Expression in Human Vascular Cells
To relate the findings in the porcine model of stent injury to human vascular cells, we 
investigated the gene expression of ADAMTS1, 4 and 5 in endothelial cells (EC) and in SMCs 
from human coronary arteries (Figure 5F). Human coronary artery ECs express ADAMTS1 and 
ADAMTS4 but neither ADAMTS5, aggrecan nor HAPLN1. In contrast, human coronary artery 
SMCs express all aggrecanases, including ADAMTS5, as well as aggrecan, versican and 
HAPLN1. Thus, resident vascular cells can contribute to the aggrecanase activity and aggrecan 
expression in the arterial wall, with ECs expressing aggrecanases but not aggrecan.
Aggrecan in the Human Vasculature 
To further validate our findings in human tissue, we used immunohistochemistry to localize 
aggrecan and aggrecan cleavage in stented human coronary arteries (Figure 6A). Coronary 
arteries with atherosclerotic plaques but without stents served as a reference control. Aggrecan 
and HPLN1 co-localized in the media of control arteries. In stented coronary arteries, staining for 
the aggrecan NITEGE neoepitope was observed predominantly below the periluminal cellular
layer and at the contacts of the stent struts with the coronary artery (Figure 6B, Supplemental
Figure 7). This was also supported by the finding that human coronary artery ECs express 
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ADAMTS1 and ADAMTS4 (Figure 5F). To further investigate aggrecan in the human 
vasculature, we compared specimens of human saphenous veins and human thoracic aorta. 
Targeted proteomics revealed that similar to versican, aggrecan was more abundant in the aorta 
than in veins (Figure 6C, Supplemental Table 7). The SLRP decorin served as a control. 
Likewise, the ADAMTS-specific aggrecan NITEGE neoepitope was detectable in the aorta 
(Figure 6D, Supplemental Figure 8). Aggrecan and ADAMTS-induced aggrecan cleavage was 
seen throughout the media of the human aorta as confirmed by immunofluorescence staining 
(Figure 6E).
Aggrecan and Aggrecanases in Mice
ADAMTS-5 is the main aggrecan degrading enzyme in mice.20 To examine the effects of 
ADAMTS-5 on the vasculature, we used proteomics to compare the ECM of aortas from mice 
lacking the catalytic domain of ADAMTS-520 with aortas from littermate controls (Supplemental
Table 8). Loss of ADAMTS-5 activity resulted in an accumulation of aggrecan (Figure 7A)
confirming the importance of aggrecanases in regulating the abundance of aggrecan in the vessel 
wall. These structural changes in the aortic wall were accompanied by an increase in the 
diameter of the thoracic, but not of the abdominal aorta (Figure 7B). Notably, cardiac output as 
measured by cardiac MRI and blood pressure were not significantly different from wildtype 
controls (Supplemental Figure 9 and Supplemental Figure 10). This genetic mouse model 
confirms the importance of aggrecanases in regulating the abundance of aggrecan in the vessel 
wall and suggests a link between aggrecanase activity and aortic diameter. 
The higher abundance of aggrecan in stented porcine coronary arteries and human aortas 
compared to veins is suggestive of mechanical stretch inducing aggrecan expression in the 
vasculature. In order to explore this potential mechanism, veins were grafted into carotid arteries 
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of mice.21 After grafting, mice were fed a diet of stable isotope labelled amino acids for 28 days 
to label newly synthesized proteins (Figure 8A). Using targeted LC-MS/MS analysis
(Supplemental Table 9), the incorporation of the stable isotope labelled amino acids was 
compared between ECM proteins in veins, vein grafts and arteries. 60% of aggrecan peptides 
were found to be labelled in the murine aorta, demonstrating active synthesis of this 
proteoglycan in the arterial wall. In contrast, labelled aggrecan peptides were undetectable in 
veins. The incorporation ratio in vein grafts, however, was comparable with the aorta. Thus, 
aggrecan synthesis was inducible in veins by exposure to arterial blood pressure. Representative 
histological sections are shown in Figure 8B, where aggrecan was markedly elevated after 
grafting. The upregulation coincided with cleavage of the versican core as indicated by staining 
for the ADAMTS-specific DPEAAE neoepitope. Thus, besides their established role in cartilage, 
aggrecan and aggrecanases are important contributors to ECM remodeling in the vasculature
upon stenting and mechanical stretch (Figure 8C).
Discussion
This is the first proteomics analysis to profile the ECM remodeling of stented coronary arteries 
and to compare the effects of DES versus BMS on the vascular ECM. Diverging from the 
traditional focus on collagens and matrix metalloproteinases, this study highlights the 
contribution of aggrecan and aggrecanases to ECM remodeling after stent implantation. Findings 
in the large animal model were validated in human specimen and followed-up in two small 
animal models. Thus far, little is known about the role of aggrecan in the vasculature and stimuli 
that induce its expression.22 We demonstrate that aggrecan is more abundant in arteries than in 
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veins, that the synthesis of aggrecan is inducible by grafting veins to arteries and that aggrecan 
abundance is influenced by aggrecanase activity in the arterial wall.  
ECM Changes in the Neointima 
The vascular ECM plays a critical role in providing structural support to the vessel wall and 
influences cell behavior and signaling. Our proteomics comparison of the neointima revealed the 
following findings: First, a more organized and structured ECM assembly in the neointima 
forming over BMS compared to DES. Presumably ECM organization occurs at an earlier stage 
in arteries treated with BMS compared to DES; Secondly, an upregulation of proteins associated 
with the regulation of calcification in neointimal lesions of arteries treated with DES. The 
upregulation of these proteins may be a protective response as demonstrated by the presence of 
MGP and SPP24 in human control arteries. MGP is thought to act as an inhibitor of 
calcification.23 Similarly, SPP24 is not osteogenic but binds to and affects the activity of BMP-
2.24 Indeed, calcification assays in human arterial SCMs demonstrated an inhibition of 
calcification under everolimus treatment. Everolimus is an inhibitor of the mechanistic target of 
rapamycin (mTOR). Further studies will need to clarify whether this observation is directly 
related to the observed ECM protein changes upon drug treatment or other drug effects. Drug 
effects could induce a phenotypic change of SMCs. This may also explain why MGP and SPP24
appear increased in normal vessels versus stented human vessels. Finally, we observed 
chondroadherin in DES stented arteries. This SLRP is mainly expressed in cartilaginous tissue25
and has been previously associated with disc degeneration26, but its expression in the vasculature 
has never been reported at the protein level. Yet, there is evidence for an association of 
chondroadherin with vascular pathology, since its transcription was found to be specifically 
induced in atherosclerotic plaques of femoral arteries.27 It remains to be elucidated, if these 
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proteins might provide a link to the increased incidence or accelerated course of de novo
atherosclerosis within DES-stented vessels.28
Early Changes upon Vascular Injury 
Our discovery-based proteomics comparison allowed an analysis of ECM proteins during early 
and late stages of vascular healing in response to stents. The early response to injury was 
independent of the applied stent type. Some changes were also observed after BA alone without 
stent insertion, indicating a response to vascular injury rather than stenting. Three different 
functional classes were increased: First, proteins involved in thrombosis such as fibrinogen, 
plasminogen, antithrombin III and thrombospondin, which is in line with findings in 
histopathological studies of platelet activation and thrombosis formation during the early stage of 
vascular healing.29 Secondly, inflammatory proteins associated with innate immunity, such as 
PTX3 and prophenin and tritrpticin, implicating the recruitment of inflammatory cells to the site 
of vascular injury. Lactadherin, for example, contributes to phagocytic removal of apoptotic 
cells30 and showed a peak expression at 7 days post-stent insertion in the DES group. Finally, 
various apolipoproteins, such as apolipoproteins E, C-III, and R and also lipoprotein lipase were 
retained. It is noteworthy that these are VLDL-associated apolipoproteins.19 We have recently 
observed that plasma levels of VLDL-associated apolipoproteins predict cardiovascular events31
and that they are also present in human atherosclerotic plaques.32
ECM Changes in the Media 
ECM changes were observed predominantly after 28 days, which is likely explained by the time 
it takes for SMCs to lay down enough new ECM. A significant increase at day 28 was seen in 
fibrillar collagens, such as type I, III and V, as well as matricellular proteins (periostin, tenascin, 
SPARC) and SLRPs like decorin, biglycan, fibromodulin, podocan and asporin. These are 
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important regulatory proteins and involved in a variety of cellular functions such as collagen 
fibril assembly, inflammation, cell proliferation, adhesion and migration as well as fibrosis.33
Generally more proteins showed a significant change in the DES compared to BMS group, with 
the differences being more pronounced at later stages. In DES, a uniform down-regulation of 
basement membrane proteins, indicative of the reduced cellularity, was accompanied by an 
increase in aggrecan, also known as cartilage-specific proteoglycan core protein.
Aggrecan in the Vasculature
Aggrecan is well studied in cartilage but its expression and function in the vasculature has only 
recently begun to be appreciated. It is the major proteoglycan in cartilage34, 35 and characterized 
by its ability to bind hyaluronan, a large carbohydrate polymer, to form even larger aggregates.36
Between its G2 and G3 domain aggrecan carries numerous glycosaminoglycans (GAGs), namely 
keratan sulfate and chondroitin sulfate chains, giving the protein an enormous amount of fixed 
negative charges (Figure 5A). These highly negatively charged GAGs provide the basis for the 
viscoelastic properties of cartilage.
Due to its water-attracting property that confers resistance to compression, aggrecan may 
be part of an adaptive response of the vasculature to absorb mechanical forces. Additionally, 
proteoglycans present growth factors and cytokines to the surrounding tissue37 and their 
interactions with other ECM components modulate a wide range of cellular responses, including 
inflammation.38 It has been suggested that the lipoprotein binding to negatively charged GAG 
side chains might contribute to atherosclerosis.22, 39 Aggrecan expression was demonstrated in 
advanced lesions of atherosclerotic aortas of ApoE/LDLr deficient mice by 
immunohistochemistry, further supporting that cartilage-associated ECM proteins may be 
involved in the pathogenesis of atherosclerosis.40 Similarly, we observed staining for aggrecan in 
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the atherosclerotic lesion of the human control coronary artery (Figure 6A, *indicates plaque 
location). Notably, a previous proteomics analysis discovered aggrecan in vascular intimal 
hyperplasia.41 Our proteomics study provides the first evidence for an upregulation of aggrecan 
after stenting and upon grafting veins from a low- to a high-pressure environment. Future studies 
are needed to investigate whether aggrecan or its cleavage products may contribute to the more 
frequent and accelerated onset of neoatherosclerosis in DES.42 Kumar et al. have recently 
reported that reduced aggrecan cleavage was associated with decreased macrophage numbers
and less atherosclerosis in Adamts4-/- ApoE-/- mice.43
Aggrecanases in the Vasculature
Besides aggrecan, the aggrecan NITEGE neoepitope was detected in porcine coronary arteries 
upon stenting. This aggrecan neoepitope is generated upon digestion by aggrecanases, but not by 
other proteases. As aggrecan is not abundant in uninjured vessels (Figure 4B), the NITEGE 
neoepitope predominantly reflects differences in substrate availability (Figure 5B). Instead, the 
versican DPEAAE neoepitope reflects the loss of aggrecanolytic activity at day 3 post stenting 
(Figure 5B). The neoepitope antibodies do not distinguish between the cleavage products of 
ADAMTS-1, ADAMTS-4 and -5 activity. ADAMTS1, ADAMTS4 and ADAMTS5, however, 
showed a notable shift in gene expression in stented porcine coronary arteries. Expression of 
ADAMTS1 and ADAMTS5 was markedly reduced upon stent implantation. Instead, ADAMTS4
was induced, in particular in BMS. Human coronary artery ECs only express ADAMTS1 and 
ADAMTS4, while human coronary artery SMCs express ADAMTS1, ADAMTS4 and ADAMTS5
as well as aggrecan. Thus, loss of arterial ECs upon stenting could contribute to the initial loss of 
aggrecanase expression in the vessel wall.44 Moreover, the effects of DES might facilitate the 
accumulation of large aggregating proteoglycans in the vessel wall. Treatment of human 
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coronary artery SMC with everolimus reduced gene expression of ADAMTS4, while expression 
levels of ADAMTS1 remained unchanged (data not shown). Upon vascular injury, however, 
inflammatory cells are likely to contribute to the ADAMTS-4 activity in the vessel wall.43
Aggrecan and its ADAMTS-cleaved fragments were also co-localized in the media of the 
human thoracic aorta. Aggrecanase activity regulates the abundance of aggrecan in the vessel 
wall as evidenced by the build-up of aggrecan in the aorta of mice lacking the catalytic domain 
of ADAMTS-5. Their vascular phenotype closely resembled recent observations in Adamts-1
heterozygous mice.45 In Adamts-1+/- mice, thoracic aortic aneurysm formation and dissection 
were induced by an increase in inducible nitric oxide synthase and medial degeneration. In our 
analysis, loss of ADAMTS-5 activity resulted in thoracic aortic dilation with a build-up of 
aggrecan. This finding extends our previous report on the catabolic properties of ADAMTS-5 on 
vascular proteoglycans and its ability to alter proteoglycan-mediated lipoprotein retention in a 
mouse model of atherosclerosis.22
Strengths and Limitations
A particular strength of our study is the combination of proteomics with a clinically relevant 
large animal model of human disease.15 In the porcine model, peak neointima growth is observed 
at 28 days after stent deployment corresponding to 6 months in human. Few changes occur 
beyond this time point, with the exception of slight neointima thinning later on.14 The pigs, 
however, are young and free of atherosclerosis. A caveat of working with porcine tissue is the 
limited availability of antibodies, and proteomics was key for a comprehensive protein analysis 
without constraints imposed by antibodies.
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Conclusions 
The effects of DES go beyond inhibition of smooth muscle cell proliferation, but have a wider 
impact on vascular remodeling by altering the composition of the ECM. The antiproliferative 
effect of DES was evident by a reduction in basement membrane proteins. Moreover, the 
decreased cellularity was accompanied by increased production of large proteoglycans like 
aggrecan and versican. Aggrecan and aggrecanases are integral components during ECM 
remodeling after stenting. A summary of our findings is provided in Figure 8C.
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Figure Legends
Figure 1. Porcine Model of Stent Injury. (A) Pigs underwent PCI with BMS/DES/BA 
treatment. Coronary arteries were retrieved for proteomics at 1, 3, 7, 14 and 28 days after stent 
deployment. The evolved neointimal lesions at day 28 were analyzed separately. In total, 45 
samples were analyzed by LC-MS/MS. (B) Quantitative analysis of the neointima was 
performed by OCT. The neointimal structure was classified into homogenous with peristrut 
attenuation/ring, heterogeneous or layered. At 14 days post-stent implantation neointimal volume 
was higher in BMS compared to DES (*P=0.025) with no significant difference at day 28. 
P=0.89 (2-way ANOVA). (C) ECM proteins were obtained using our previously published 
extraction procedure, followed by LC-MS/MS analysis of the deglycosylated tryptic peptides.
Figure 2. ECM Remodeling in the Neointima. (A) Heat map of proteins with differential
abundance. n=7 per group (t-test with unequal variance) (B) Proteins involved in the regulation 
of calcification (SPP24, MGP, BMP1) and chondroadherin were predominantly found in the DES 
group. *P<0.05. TIC=total ion current. BMP 1, chondroadherin and SPP24 were undetectable in 
the control group, thus a t-test was not performed. (C) Everolimus treatment reduced SMC 
calcification as revealed by Alizarin Red staining and o-Cresolphthalein Complexone assay. 
n=triplicates of 4 independent experiments. ***P<0.001 (t-test with unequal variance). (D) MGP 
and SPP24 in human stented and control coronary arteries. Scale bars=1 mm.
Figure 3. ECM Remodeling in the Media. (A-C) Heat maps of ECM proteins with differential 
abundance at different time points. BMS/DES: n=3 per time point. P<0.05 (1-way ANOVA). 
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BA: n=3-4 per group. P<0.05 (t-test with unequal variance). (D) Number of significant protein 
changes in BA late compared to BMS and DES at day 28. (E) Number of proteins with 
differential abundance between DES versus BMS at day 1, 3, 7 and 28 post stent implantation.
Abbreviations: ITI heavy chain H2, inter-alpha-trypsin inhibitor heavy chain H2; PTX3, 
pentraxin-related protein PTX3; sFRP-1, secreted frizzled-related protein 1; IGF, insulin-like 
growth factor; SD, superoxide dismutase; LTBP, latent-transforming growth factor beta-binding 
protein; AE, adipocyte enhancer.
Figure 4. ECM Composition in DES and BMS in the Media. (A) Volcano plot of 
differentially expressed proteins between DES and BMS at day 28. n=3 per group (t-test with 
unequal variance). PGCA, aggrecan; HPLN1, hyaluronan and proteoglycan link protein 1 (B) 
Changes in aggrecan, versican and HPLN1 protein abundance at day 1, 3, 7 and 28 post stent 
implantation. n=3 per group. *P<0.05 (t-test with unequal variance). TIC, total ion current. (C) 
Corresponding gene expression in stented (n=3 per time point) and control unstented coronary 
arteries (n=6); Gene expression values were normalized to unstented control arteries. Linear 
regression analysis for P value for trend. HAPLN1, gene name for hyaluronan and proteoglycan 
link protein 1.
Figure 5. Aggrecanase Expression in the Porcine Model of Stent Injury and Comparison to 
Human Vascular Cells. (A) The aggrecan neoepitope NITEGE and the versican neoepitope 
DPEAAE are generated by ADAMTS cleavage. (B) Aggrecan NITEGE and versican DPEAAE 
neoepitopes in DES at day 1, 3, 7 and 28 post stent implantation. n=3 per time point. (C)
Differences between BMS and DES at day 28. n=4 per group. (D) Gene expression of 
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ADAMTS1, 4 and 5 in porcine tissue. n=3 per time point for BMS/DES; n=6 for control coronary 
arteries. Gene expression values were normalized to unstented control arteries. Linear regression 
analysis for P value for trend. (E) Basal ADAMTS expression levels in porcine coronary arteries. 
Cycle threshold (CT) values by qPCR are given as 40-CT (higher values indicate higher 
abundance). n=6 per group. (F) Gene expression of ADAMTS1, 4 and 5 as well as versican, 
aggrecan and HAPLN1 in ECs and SMCs of human coronary arteries. Cycle threshold (CT) 
values by qPCR are given as 40-CT (higher values indicate higher abundance). HCAEC, human 
coronary artery endothelial cells; HCASMC, human coronary artery SMCs; n=triplicates of 3
independent cell passages. ***P<0.001 (t-test with unequal variance).
Figure 6. Aggrecan in the Human Vasculature. (A) Localization of aggrecan, the aggrecan 
NITEGE and versican DPEAAE neoepitopes (neo), and HPLN1 in stented and control human 
coronary arteries with presence of atherosclerosis (*). Arrows mark the contacts of the stent 
struts with coronary artery. Scale bars=1 mm. (B) Co-localization of aggrecan (Alexa 633, 
displayed in green) and aggrecan NITEGE neoepitope (Alexa 568, displayed in red) in human 
stented coronary arteries by immunofluorescence. Note the presence of aggrecan fragments at 
the contacts of the stent struts with the artery and in the subendothelial layer (zoomed-in areas). 
Overview image 20x, scale bar=500 μm; Zoomed-in areas 60x, scale bar=25 μm. (C) Adjusted 
peak area for aggrecan, versican and decorin in the human thoracic aorta and saphenous veins as 
determined by targeted proteomics. n=7 per group. *P<0.05, **P<0.01 (t-test with unequal 
variance). (D) Immunoblots for the aggrecan NITEGE neoepitope and versican in the human 
thoracic aorta and saphenous veins. The SLRP decorin served as a loading control. n=4 per 
group. (E) Co-localization of aggrecan (Alexa 633, displayed in green) and aggrecan NITEGE 
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neoepitope (Alexa 568, displayed in red) in human aorta visualized by immunofluorescence. 
Elastin fibers in white (autofluoresence with 488nm laser excitation captured in the green 
emission channel). Control sections stained with isotope IgGs. Magnification 60x, scale bars=20 
μm. 
Figure 7. Aggrecan and Aggrecanases in the Murine Aorta (A) Volcano plot of differentially 
expressed proteins between the aorta of wild-type littermate controls (WT) and mice lacking the 
catalytic domain of ADAMTS-5 (Adamts5 ǻFDW). n=6 (WT), n=5 (Adamts5 ǻFDW), t-test with 
unequal variance. PGCA, aggrecan; MIME, mimecan; VTNC, vitronectin. (B) Aortic diameters 
of aortic ring (AoR), ascending aorta (AsAo) and abdominal aorta (AbAo) as measured by 
ultrasonography. Representative ultrasound images are shown, values are represented as box-
and-whisker plots. n=5 per group *P<0.05 (t-test with unequal variance). 
Figure 8. Aggrecan in Vascular Remodeling. (A) The isogenic venae cavae were grafted to 
carotid arteries of mice fed a diet with stable isotope labelled amino acids. Incorporation ratios 
for aggrecan, versican and decorin in interposition grafts, vena cava inferior and aortas. n=8-9
per group. N.D.=not detectable. (B) Immunostaining for aggrecan, the versican DPEAAE 
neoepitope and decorin. Magnification 10x, scale bars=200 μm. (C) Summary. Changes in 
ADAMTS expression accompany the increase of the large aggregating proteoglycans aggrecan 
and versican post-stenting.
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SUPPLEMENTAL MATERIAL 
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SUPPLEMENTAL METHODS 
OCT Image Analysis in Pigs. OCT imaging was performed at stent implantation and 
at follow-up using the ILUMIEN OPTIS imaging system (St. Jude Medical, US). The OCT 
probe (mid marker of the OCT Dragonfly catheter) was positioned 5 mm distally to the 
analysed stent. All OCT imaging was performed using automated pullback triggered by hand 
injection of contrast. Every 1 mm of the stent was scrutinized by OCT to assess minimal lumen 
area, stent struts apposition, stent struts coverage and neointimal volume. Qualitative analysis 
of neointima was performed classifying the neointimal structure into heterogeneous, layered 
or homogenous with peristrut attenuation or ring.1 If peristrut attenuation was visible in the 
whole circumference of the stent at the single OCT cross-sectional frame, the peristrut ring 
was recognized. The data was analysed using the OCT image analysing system, CAAS 
IntraVascular (version 1.1, Pie Medical Imaging).  
Deglycosylation of ECM Extracts. GuHCl was removed by ethanol precipitation and 
the proteins were deglycosylated using deglycosylation enzymes. The deglycosylation 
enzymes included: chondroitinase ABC (1:100), keratanase (1:500) and heparinase II (1:500) 
(all from Sigma-Aldrich) for the removal of GAG side chains; 2 different debranching enzymes 
including α2-3,6,8,9-Neuraminidase (1:200) and ß-N-acetylglucosaminidase (1:200) as well 
as O-glycosidase for the removal of the remaining O-linked sugars (1:200) (all from Millipore). 
After 24 h incubation samples were speed-vac dried. PNGase F (1:200, from Millipore) was 
added together with 18O labelled water (Sigma-Aldrich) for another 48 h of incubation.  
Generation of Custom-made Porcine ECM Protein Database. To achieve the best 
peptide sequence coverage by LC-MS/MS, and identify as many proteins as possible, a 
search database containing a comprehensive list of porcine ECM proteins was generated. 
Previously reported cardiovascular ECM proteins identified in human, porcine and murine 
cardiovascular tissues2-4 were searched for their porcine sequences in the Uniprot protein 
database. Porcine sequences of many of these proteins were found and retrieved from Uniprot 
either as annotated proteins or after blasting the human sequence against non-annotated, 
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uncharacterized porcine proteins. The remaining ECM proteins with no matching sequences 
in Uniprot were deduced from public nucleotide databases (including mRNA annotated 
sequences and expressed sequence tags [EST]) using tBLASTtn. Exclusively the best 
matches (≥ 90% identity) were assigned to a protein sequence and retrieved for the database. 
The final database contained a total of 270 manually included porcine ECM protein 
sequences. All canonical human sequences were used as background in order to obtain a 
database suitable for search algorithms (i.e. Mascot). To avoid redundancies all human ECM 
proteins were manually removed and replaced by their porcine counterparts. 
Human Tissue. All procedures involving use of human tissues were approved by a 
local Research Ethics Committee (London, United Kingdom, Wandsworth research ethics 
committee approval REC number 08/H0803/257). Normal saphenous vein specimens were 
obtained by surgical resection in consented patients undergoing coronary artery bypass 
surgeries; the segment of the saphenous vein near the knee level was collected for analysis 
from each patient. Control aortic samples from consented patients without connective tissue 
disorder were obtained upon aortotomy performed during routine aortic valve replacement 
from positions of the ascending aorta that were free of macroscopically evident vascular 
pathology. All samples were snap frozen following surgical removal. There were no known 
potential confounders during sampling of clinical specimens and tissues.  
Immunoblot Analysis. Porcine samples: 10 µg of deglycosylated GuHCl extracts of 
stented porcine coronary arteries (n=3 first cohort; n=4 second cohort day 28) were denatured 
at 95 °C for 5 min and reduced with sample buffer (0.1 mol/l Tris, pH 6.8, 40% glycerol, 2% 
SDS, 2% beta-mercaptoethanol and 0.02% bromophenol blue) and separated by SDS-PAGE. 
Subsequently proteins were blotted to a nitrocellulose membrane, which was blocked in 5% 
milk and incubated with primary antibodies to the aggrecan NITEGE neoepitope (Thermo, AF-
PA1-1746) and the versican DPEAAE neoepitope (Abcam, ab19345) over night. After 3 
washes (15 min each) with PBS-Tween, the membranes were treated with appropriate HRP-
conjugated light chain-specific detection antibody (1:5000, Jackson Immunoresearch) for 1 h. 
The membranes were washed again 3 times and developed using enhanced 
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chemiluminscence (ECL, GE Healthcare) on a Xograph processor in 30 sec increments. 
ImageJ software was used for densitometric quantification. Human samples: Same protocol 
was applied. 7 μg of GuHCl extracts of human thoracic aorta and saphenous vein were loaded 
per lane. Antibodies against the aggrecan NITEGE neoepitope (Thermo, AF-PA1-1746), 
versican (Santa Cruz, sc-25831) and decorin (Thermo Fisher PA5-19151) were used. 
Cell Culture.  Endothelial cells: Human coronary artery endothelial cells were obtained 
from PromoCell (C-12222) and cultured on 0.04% gelatine in appropriate Endothelial Cell 
Growth Medium (PromoCell C-22020) at 37 °C in a humidified atmosphere of 95% air/5% 
CO2. Cells were washed with cold PBS twice and scraped off the surface with Qiazol. RNA 
was extracted as described below and reversely transcribed using SuperScript® VILO 
MasterMix (Life Technologies). The experiments were carried out with cells at passage 4-9.  
Smooth muscle cells: Human coronary artery smooth muscle cells (HCASMCs) were obtained 
from PromoCell (C-12511) and grown in M199 medium (GibcoTM) on 0.04% gelatine. For 
experiments cell passages 7-11 were used.  
Calcification Assay. Human aortic SMCs were cultured in M199 supplemented with 
5% fetal bovine serum and treated with everolimus 20 nM or equivalent concentration of 
DMSO as vector control. Everolimus was a kind gift from Novartis, Switzerland and was 
shipped under a material transfer agreement with King’s College London. To induce 
mineralization the medium was supplemented with calcium (2.7 mM) and phosphate (2.5 
mM).5 Calcification was visualized after fixation with 4% formaldehyde using Alizarin red (2% 
weight/volume, pH 4.2) and quantified spectrophotometrically using the o-Cresolphthalein 
complexone assay after 8 days of Ca/P treatment +/- everolimus. Calcium concentrations 
were normalized to protein concentrations determined by the Biorad DC protein assay. Each 
experiment was carried out in triplicates and cells were used at passages between 10-12. 
Real-time Polymerase Chain Reaction (qPCR). RNA from the porcine tissue was 
extracted using the miRNeasy Mini kit (Qiagen) according to the manufacturer’s instructions. 
For gene expression analysis, porcine RNA was reversely transcribed using SuperScript® 
VILO MasterMix (Life Technologies). Taqman® assays were used to assess the expression 
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of individual target genes. Diluted reverse transcription products were combined with 
TaqMan® expression (Applied Biosystems) and TaqMan® Universal PCR Master Mix No 
AmpErease® UNG (2x) to a final volume of 5µl. For ADAMTS-1, -4 and -5 expression analysis 
in porcine tissue samples, SYBRgreen primers were designed and the reaction volume was 
set up with SYBR Select Master Mix (2x): 
ADAMTS1: fwd CGTGAACAAGACCGACAAGA/ rev AACTCCTCCACCACACGTTC; 
ADAMTS4: fwd CCCCATGTGCAACGTCAAG/ rev AGTCTCCACAAATCTGCTCAGTGA; 
ADAMTS5: fwd TCACGAAATTGGACATCTGC/ rev CTGGTCAGGATGGAGGACAT. 
ACTB: fwd TCTGGCACCACACCTTCT/ rev GATCTGGGTCATCTTCTCAC).  
The qPCR reaction was performed in a ViiA7 qPCR instrument (ThermoFisher Scientific) 
under following conditions: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15sec and 60 
°C for 1 min. Samples were normalized to the expression of β-actin (ACTB) for gene 
expression targets. Target relative amounts were quantified using the 2-ΔΔCT method.6 
Vein Graft Surgery in Mice. An established mouse model of venous bypass graft was 
used by grafting isogeneic venae cavae to common carotid arteries of female C57BL/6J mice 
(Jackson laboratories), as described previously.7 Briefly, mice were anaesthetised by 
intraperitoneal injection of ketamine (75 mg/kg) and medetomidine HCL (1 mg/kg). A segment 
(approx. 1 cm) of vena cava from a donor animal was grafted end-to-end to carotid arteries 
using a cuff technique. Grafts and vena cava were harvested at time point 3, 7 and 28 days 
post-surgery for histological characterization. Other mice were fed a SILAC (stable isotope 
labeling with amino acids in cell culture) diet containing heavy lysine ad libitum and had access 
to water. Stable isotope-labelled mouse feed was obtained from Silantes (Munich, Germany). 
Mice were euthanized by anesthetic overdose 28 days postoperatively. The vein grafts were 
harvested by cutting the implanted segments from the native vessels at the cuff end together 
with the vena cava and the aorta. The vessels were processed using the ECM extraction 
method as described above. GuHCl extracts were subject to tryptic digests and used for 
targeted proteomics analysis as described in the following paragraph.  
 
6 
Targeted Proteomic Analysis.  
SILAC-fed mice tissue: Proteotypic peptides were scheduled using the retention time 
obtained from untargeted experiments with same HPLC configuration and eluting gradient. All 
proteotypic peptides were lysine (K)-terminated to allow quantification of SILAC incorporation. 
Skyline software (MacCoss Lab, University of Washington, Seattle) was used first to predict 
collision energies and optimize retention times, and second to quantify peak areas for MS2 
ions after Parallel Reaction Monitoring (PRM). The identity of a specific peptide was confirmed 
by the presence of multiple transitions at the same retention time. Retention time windows 
were set +/- 4 min. All peaks were manually reviewed and integrated. A mass tolerance of 
5ppm was used as a minimum requirement for fragment ions. SILAC incorporation rates were 
derived from the proportion between ions derived from peptides containing either heavy or 
light lysines (i.e. Lys152 and Lys146) using the following formula:  Incorporation rate = [Heavy] 
/ [Heavy + Light]. The intensities of heavy and light peptides were calculated using the peak 
areas after MS2. The following peptides were used for targeted proteomics in mice tissue: 
aggrecan GDPETSVSGVGDDFSGLPSGK (G1172 – K1192), TVYLYPN[+3]QTGLPDPLSK 
(T661 – K677); versican VSVPTHPDDVGDASLTMVK (V101 – K119); decorin DLHTLILVNNK 
(D101 – K111), NSGIENGAFQGLK (N183 – K195), and VVQC[+57]SDLGLDK (V59 – K69).  
Human vascular tissue: For targeted proteomics in human aorta and veins same 
methodology was applied except the SILAC labeling. Following peptides were used: aggrecan 
C[+57]GGNLLGVR (C318 - R326), versican LATVGELQAAWR (L277 - R288), decorin 
NLHALILVNNK (N106 - K116). 
Immunofluorescence Staining in Human Vessels. Vessels were processed as 
described for immunohistochemistry. Sections of 5 µm (aorta) or 3 µm (coronary artery) were 
incubated with 0.5 unit/ml chondroitinase ABC (Sigma C3667) for 1 h at 37 °C. After blocking 
with 10% donkey serum in PBS for 1 h, sections were co-incubated with primary antibodies to 
aggrecan (1:10; Abcam, ab3778) and the aggrecan NITEGE neoepitope (1:200; Thermo, AF-
PA11746) as well as matched isotope IgGs for negative controls. Secondary antibodies (Life 
Technology) were applied as indicated. Cell nuclei were stained with DAPI (Life Technology). 
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Sections were visualized with a 20x CFI S Plan Fluor ELWD ADM objective or 60x Plan Apo 
VC NA 1.40 Nikon using an inverted Nikon NI-E microscope equipped with a Yokogawa CSU-
X1 Spinning disk confocal unit and an Andor iXon 3 EM-CCD camera. Images were acquired 
using NIS-elements 4.0 software, and represent a maximum projection image of a Z-stack of 
0.5 µm steps compassing 9 µm. 
Immunohistochemistry in Murine Vein Grafts. For histological analysis, mice 
tissues were fixed overnight with 10% formalin before being dehydrated in graded ethanol 
baths, cleared in xylene and embedded in paraffin. Histological sectioning began at the centre 
of the graft to avoid the effects of the cuff. 3 μm-thick cross-sections were made throughout 
the dissected tissue. Immunohistochemical analysis was performed using antibodies to 
aggrecan (1:100; Abcam, ab36861), the DPEAAE neoepitope of versican (1:100; Abcam, 
ab19345) and decorin (1:100; Sigma-Aldrich, SAB2100539). Negative controls were 
generated with 10% solution of normal goat serum (Vector labs). Slides were incubated with 
the primary antibody overnight at 4 °C. After washing, a secondary antibody (1:400, biotin 
conjugated goat anti-rabbit IgG; Vector labs) was applied for 30 min at room temperature. 
Specific immunohistochemical staining was detected by thoroughly washing slides and 
subsequently incubating with horseradish peroxidase (HRP) labelled avidin D (Vector labs) 
for 2 h at room temperature. The final detection step was carried out using a DAB 
(diaminobenzidine) peroxidase kit according to the manufactures instructions (Vector Labs). 
Sections were counterstained with haematoxylin and mounted.  Images were taken by a Leica 
DM 2000 microscope interfaced to LAS software (version 4.3.0; Leica microsystems). 
Adamts5 Δcat Mice. Animal experiments were approved by the U.K. authorities 
(licensed to Q. Xu, PPL70/7266). 10 to 12-week-old wild-type mice (WT) or mice lacking the 
catalytic domain of Adamts5 (Adamts5 Δcat)8 were utilized for the following experiments. For 
each of the experiments between 5 - 7 mice per group were utilized. Aortas were dissected 
from WT or Adamts5 Δcat mice from the aortic root to the iliac bifurcation. Periaortic fat and 
lymph nodes were removed under a dissecting microscope. Cleaned aortas were washed, 
diced and subjected to a three-step extraction method in order to enrich the ECM proteins as 
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described under ‘ECM extraction’. 15 µg of deglycosylated proteins of the GuHCl fraction were 
subjected to in-solution digestion and analysed by LC-MS/MS as described in the manuscript 
under ‘proteomics analysis in porcine tissue’. The raw files were searched against the UniProt 
mouse database (UniProtKB/Swiss-Prot Release 2016_02, 16765 protein entries).   
Murine Ultrasound Measurements. Animals were placed in the induction chamber 
and anaesthetised by using 5% isoflurane mixed with 1l/min of 100% oxygen for 45 sec - 1 
min. Next, mice were placed in a supine position on the heating pad to maintain body 
temperature with embedded ECG. 1-1.5% isoflurane mixed with 1 L/min 100% oxygen was 
subsequently used to maintain a steady state of sedation levels during the entire procedure. 
A rectal probe was gently inserted to continuously monitor the body temperature. Two-
dimensional (2D) echocardiographic images of cardiovascular anatomy were obtained by a 
single operator. Standard and modified parasternal long axis (PLAX), suprasternal (SS), 
longitudinal and transverse abdominal (LA, TA) views were obtained using Visual Sonics Vevo 
2100. Aortic root dimensions (aortic annulus, sinuses of Valsalva, sinotubular junction) were 
measured in PLAX. Ascending aortic dimensions were measured in SS where possible, and 
modified PLAX if SS views were considered inadequate, in systole and diastole. Abdominal 
aorta measurements were made in the TA view. All measurements were performed offline on 
(Vevo software version 1.7) by two independent investigators.  
Murine Cardiovascular Magnetic Resonance Imaging (CMR). CMR imaging was 
performed on a 7T horizontal MR scanner (Varian, Palo Alto, CA) with mice positioned in the 
prone position. The gradient coil had an inner diameter of 12 cm, 1,000 mT/m (100G/cm) 
gradient strength, and rise-time of 120 µs. A quadrature transmit/receive coil (RAPID 
Biomedical). Anesthesia was maintained with 1.5% isoflurane/98.5% oxygen, and body 
temperature was maintained at 37 °C using a warm air fan (SA Instruments, Stony Brook, 
NY). The ECG was monitored via 2 metallic needles placed subcutaneously into the front 
paws. A pressure-transducer for respiratory gating was placed on the abdomen. To 
synchronize data acquisition with the ECG and to compensate for respiratory motion, 
simultaneous ECG triggering and respiration gating (SA Instruments) were applied. Late 
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gadolinium enhancement MRI was performed 20 min after intraperitoneal injection of a 30 µl 
bolus of 0.5 mmol/kg gadolinium-diethylenetri-amine-pentaacetic acid (Magnevist, Schering 
Healthcare). Cine-MRI was used to acquire gadolinium enhanced images. Ejection fraction 
was obtained from cine-MR images according to a previously published method. 9  
Murine Blood Pressure Measurements. Blood pressure was measured directly via 
implantable radio telemetry device for collection of continuous blood pressure data. Around 
200 values were acquired every 5 minutes for 18/20 hours. For each mouse the average 
value of these 200 points was considered.
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Supplemental Table I. Sample characteristics. 
 
 
Clinical characteristics of pigs (lifetime, sex, weight, age at intervention) and PCI specific parameters 
are shown, including used stent type, balloon/stent size at implantation, average vessel diameter 
(AVD) as measured by angiography before dilatation, final size of stent/balloon after expansion 
(target overstretch) as well as the applied inflation pressure. Macroscopically neointima formation 
was detected in all arteries at 28 days, independent of stent type. Prox = proximal, dis = distal.
Media 
Lifetime 
[days] Stent/Balloon 
Coronary 
artery Sex 
Weight 
[kg] 
Age 
[months] 
Size    
[mm] 
AVD 
[mm] 
Target 
overstretch 
[mm] 
Inflation 
[atm] 
1 
BMS 
LAD M 35 3 3.5x15 3.4 4.1 22 
LCX dis M 35 3 3.5x15 3.0 3.5 12 
RCA prox F 38 3 3.5x15 3.0 3.6 12 
DES 
LAD F 38 3 3.0x15 3.0 3.5 23 
LCX prox F 38 3 3.5x15 3.1 3.7 12 
RCA M 35 3 3.0x15 3.0 3.6 24 
BA early LCX prox M 35 3 3.5x15 3.0 3.5 28 RCA dis F 38 3 3.5x15 2.9 3.5 12 
3 
BMS 
LAD M 45 4 3.0x15 2.7 3.2 15 
LCX F 45 4 3.0x15 2.8 3.3 16 
RCA dis M 45 4 3.0x15 2.7 3.2 14 
DES 
LAD F 45 4 3.0x15 2.8 3.3 14 
LCX M 45 4 3.0x15 2.6 3.1 11 
RCA prox F 45 4 3.0x15 2.7 3.0 14 
BA early RCA prox M 45 4 3.0x15 2.8 3.4 16 RCA dis F 45 4 3.0x15 2.5 3.0 14 
7 
BMS 
LAD prox M 32 3 3.5x15 3.1 3.7 14 
LCX prox F 33.5 3 3.5x15 2.9 3.4 10 
RCA prox F 33.5 3 3.0x15 2.8 3.4 18 
DES 
LAD prox F 33.5 3 3.5x15 3.0 3.5 9 
LCX prox M 32 3 3.5x15 3.0 3.6 9 
RCA prox M 32 3 3.0x15 2.4 2.9 10 
14 BA late LCX prox M 33 3 3.0x15 2.5 2.9 14 
28 
BMS 
LAD prox F 29 3 3.5x15 2.9 3.5 10 
LCX prox F 28 3 3.0x15 2.5 3.0 10 
RCA prox F 28 3 3.0x15 2.0 2.4 10 
DES 
LCX prox F 29 3 3.5x15 3.0 3.5 9 
RCA medial F 29 3 3.5x15 3.1 3.5 9 
RCA dis F 28 3 3.0x15 2.0 2.4 9 
BA late LAD F 28 3 3.5x15 2.9 3.5 10 RCA prox F 29 3 3.5x15 2.9 3.5 12 
          
          
Neointima 
Lifetime 
[days] Stent-type 
Coronary 
artery Sex 
Weight 
[kg] 
Age 
[months] 
Size    
[mm] 
AVD 
[mm] 
Target 
overstretch 
[mm] 
Inflation 
[atm] 
28 
BMS 
LAD prox F 29 3 3.5x15 2.9 3.5 10 
LCX prox F 28 3 3.0x15 2.5 3.0 10 
RCA prox F 28 3 3.0x15 2.0 2.4 10 
RCA prox M 47 3.5 3.5x8 3.0 3.6 12 
RCA dis M 47 3.5 3.0x12 2.8 3.4 20 
RCA prox M 48 3.5 4.0x14 3.4 4.1 12 
LCX M 48 3.5 3.0x15 2.8 3.4 16 
DES 
LCX prox F 29 3 3.5x15 3.0 3.5 9 
RCA medial F 29 3 3.5x15 3.1 3.5 9 
RCA dis F 28 3 3.0x15 2.0 2.4 9 
LAD dis M 47 3.5 3.0x15 2.6 3.1 12 
LCX med M 47 3.5 3.5x18 3.2 3.9 18 
RCA dis M 48 3.5 3.5x15 2.9 3.8 12 
LAD med M 48 3.5 3.0x18 2.4 2.9 9à12 
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Supplemental Table II. Extracellular proteins identified by proteomics analysis in the 
neointima of stented porcine coronary arteries. 
 
Identified Proteins  UniProt ID 
MW 
(kDa) 
BMS         
Av±SD 
DES             
Av±SD 
FC 
DES/BMS P FDR 
Adipocyte enhancer-
binding protein 1 F1SSF7_PIG 128 165.6±93.4 142.4±32.5 0.9 0.554 0.725 
Aggrecan F1SKR0_PIG 238 41.2±69.5 70.8±34.1 1.7 0.338 0.559 
Agrin I3LGD9_PIG 216 116.6±65.1 128.5±40.2 1.1 0.688 0.799 
Alpha-1-antitrypsin*  A1AT_PIG 47 33.6±30.2 11.8±8.0 0.4 0.109 0.305 
Alpha-2-HS-glycoprotein FETUA_PIG 38 472.0±223.6 263.1±75.3 0.6 0.050 0.203 
Annexin A1  ANXA1_PIG 39 231.1±142.4 129.4±45.3 0.6 0.113 0.305 
Annexin A2  ANXA2_PIG 39 571.0±247.8 430.9±65.4 0.8 0.192 0.391 
Antithrombin-III  Q7M364_PIG 49 92.2±38.7 71.2±18.1 0.8 0.228 0.433 
Apolipoprotein A-I  APOA1_PIG 30 619.6±234.8 549.4±270.4 0.9 0.614 0.775 
Apolipoprotein A-IV  APOA4_PIG 43 7.6±4.0 10.9±8.3 1.4 0.362 0.581 
Apolipoprotein B* Q29021_PIG 300 27.7±33.0 11.8±15.5 0.4 0.278 0.480 
Apolipoprotein C-III  APOC3_PIG 11 16.2±9.2 18.8±11.9 1.2 0.658 0.799 
Apolipoprotein E  APOE_PIG 37 76.6±73.2 63.8±70.2 0.8 0.745 0.840 
Apolipoprotein H I3LGN5_PIG 29 141.2±84.9 128.0±131.6 0.9 0.827 0.881 
Apolipoprotein R  APOR_PIG 23 27.0±17.6 40.8±22.6 1.5 0.228 0.433 
Asporin F1SUE4_PIG 42 137.6±70.1 80.2±33.0 0.6 0.083 0.257 
Biglycan  K7GP55_PIG 41 1767.1±214.9 1130.6±169.0 0.6 0.000 0.007 
Bone morphogenic protein 
1* F1RMB2_PIG 114 0.0±0.0 4.9±5.6 n/a n/a n/a 
Carboxypeptidase-like 
protein X2 F1SEC6_PIG 86 24.9±26.1 15.8±5.3 0.6 0.397 0.592 
Cathepsin D  Q4U1U3_PIG 44 79.6±46.1 34.5±24.3 0.4 0.047 0.203 
Cathepsin G F1SGS1_PIG 29 0.4±1.0 0.0±0.0 0.0 n/a n/a 
Cathepsin Z* A5GFX7_PIG 34 2.9±5.6 0.0±0.0 0.0 n/a n/a 
Chitinase-3-like protein 1  CH3L1_PIG 43 31.8±39.8 2.6±4.6 0.1 n/a n/a 
Chondroadherin* CHAD_HUMAN 40 0.8±1.3 35.6±25.3 46.5 n/a n/a 
Clusterin  CLUS_PIG 52 149.6±28.5 301.7±99.0 2.0 0.006 0.083 
Coatomer subunit alpha* F1RJX8_PIG 138 16.3±14.7 14.6±7.2 0.9 0.796 0.872 
Collagen alpha-1 (I) CO1A1_PIG 100 2798.6±873.9 1842.9±504.6 0.7 0.032 0.182 
Collagen alpha-1 (III) F1RYI8_PIG 139 698.6±329.3 224.0±93.9 0.3 0.008 0.092 
Collagen alpha-1 (IV) M3V819_PIG 160 49.1±20.8 47.8±10.7 1.0 0.887 0.920 
Collagen alpha-1 (V) F1S021_PIG 182 205.5±64.2 137.6±35.9 0.7 0.036 0.188 
Collagen alpha-1 (VI) CO6A1_PIG 43 36.4±27.4 19.2±7.1 0.5 0.155 0.342 
Collagen alpha-1 (VIII) F1SKX7_PIG 73 14.1±5.2 19.8±5.7 1.4 0.075 0.252 
Collagen alpha-1 (XI) F1S571_PIG 159 19.4±20.4 10.9±12.2 0.6 0.369 0.581 
Collagen alpha-1 (XII) COCA1_PIG 229 484.1±151.0 218.6±50.9 0.5 0.003 0.063 
Collagen alpha-1 (XV) COFA1_PIG 27 68.8±36.2 137.6±20.6 2.0 0.002 0.060 
Collagen alpha-1 (XVIII) COIA1_PIG 62 216.1±61.8 248.4±36.7 1.1 0.263 0.468 
Collagen alpha-1 (XX) COKA1_PIG 192 1190.7±613.9 440.1±145.6 0.4 0.017 0.139 
Collagen alpha-2 (I) F1SFA7_PIG 129 1305.6±466.3 845.6±261.8 0.6 0.048 0.203 
Collagen alpha-2 (IV) F1RLL9_PIG 161 89.9±26.6 82.8±13.2 0.9 0.542 0.721 
Collagen alpha-2 (V)  Q59IP2_PIG 145 134.8±55.5 66.7±26.4 0.5 0.018 0.139 
Collagen alpha-2 (VI) I3LQ84_PIG 106 124.7±110.6 57.2±29.7 0.5 0.163 0.350 
Collagen alpha-3 (V)  Q59IP1_PIG 172 2.1±5.5 0.0±0.0 0.0 n/a n/a 
Collagen alpha-3 (VI) I3LUR7_PIG 342 371.3±357.3 92.9±63.2 0.3 0.086 0.258 
Collagen alpha-6 (VI) CO6A6_PIG 250 8.1±12.9 0.0±0.0 0.0 n/a n/a 
Complement C3  CO3_PIG 187 805.6±730.5 687.7±404.2 0.9 0.717 0.818 
Complement component 
C8B* A0SEH2_PIG 69 23.1±18.9 27.3±18.4 1.2 0.682 0.799 
Complement component 
C9  A0SEG9_PIG 62 2.4±1.5 6.9±6.4 2.9 0.115 0.305 
Connective tissue growth 
factor  CTGF_PIG 38 1.2±3.1 6.3±7.4 5.4 n/a n/a 
Decorin  PGS2_PIG 40 185.4±59.1 104.5±81.3 0.6 0.057 0.208 
Dermatopontin  DERM_PIG 22 55.8±23.6 38.1±14.2 0.7 0.121 0.314 
Dystroglycan  I3LD20_PIG 95 3.3±4.4 1.7±2.5 0.5 n/a n/a 
EMILIN-1 F1SDQ5_PIG 107 64.1±34.1 62.4±12.4 1.0 0.905 0.930 
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EMILIN-2* F1SBC8_PIG 106 0.5±1.2 0.0±0.0 0.0 n/a n/a 
Fibrillin-1  FBN1_PIG 313 23.8±28.1 10.4±10.8 0.4 0.274 0.480 
Fibrinogen beta chain  F1RX37_PIG 56 5135.7±4558.0 4487.1±2656.8 0.9 0.752 0.840 
Fibrinogen gamma chain F1RX35_PIG 50 4287.0±3582.2 3875.7±2485.5 0.9 0.808 0.872 
Fibromodulin F1S6B5_PIG 44 549.7±94.2 350.4±115.8 0.6 0.004 0.071 
Fibronectin F1SS24_PIG 272 10317.1±3240.8 11617.1±2173.3 1.1 0.398 0.592 
Fibronectin type III 
domain-containing protein 
1 F1SB59_PIG 204 26.8±41.2 11.7±9.9 0.4 n/a n/a 
Fibulin-1  F1SM61_PIG 78 120.4±47.0 149.3±43.4 1.2 0.255 0.465 
Fibulin-2 FBLN2_PIG 54 20.9±22.8 16.5±14.2 0.8 0.670 0.799 
Fibulin-3 F8SIP2_PIG 54 190.2±94.1 155.0±53.8 0.8 0.412 0.602 
Fibulin-4* F1RU22_PIG 49 36.2±11.8 38.3±7.7 1.1 0.694 0.799 
Fibulin-5 F1SD87_PIG 50 300.0±137.6 351.1±84.6 1.2 0.422 0.608 
Filamin-C* F1SMN5_PIG  290 310.9±151.2 387.0±102.9 1.2 0.295 0.502 
Galectin-1  LEG1_PIG 15 353.4±61.5 265.0±52.4 0.7 0.014 0.131 
Galectin-3  A3EX84_PIG 27 87.2±91.7 29.8±14.2 0.3 0.151 0.342 
Galectin-3-binding protein M3V7X9_PIG 61 14.3±11.8 52.4±42.3 3.7 0.056 0.208 
Galectin-9* F1RJ33_PIG 40 1.3±1.7 0.3±0.6 0.3 n/a n/a 
Gelatinase A*  Q95JA4_PIG 74 6.6±8.5 0.5±0.9 0.1 n/a n/a 
Gelsolin  GELS_PIG 85 1242.1±295.1 1123.4±194.5 0.9 0.394 0.592 
Hemicentin-1* HMCN1_PIG 180 1.3±2.2 0.7±1.8 0.5 n/a n/a 
Hyaluronan and 
proteoglycan link protein 1  HPLN1_PIG 40 7.7±10.8 16.2±15.4 2.1 0.257 0.465 
Insulin-like growth factor-
binding protein 7  C7EDN1_PIG 29 395.2±201.4 468.1±122.0 1.2 0.432 0.615 
Inter-alpha-trypsin inhibitor 
heavy chain H1* ITIH1_PIG 100 145.1±77.4 143.1±46.0 1.0 0.955 0.964 
Inter-alpha-trypsin inhibitor 
heavy chain H2  ITIH2_PIG 105 95.1±63.8 63.5±16.7 0.7 0.247 0.462 
Intercellular adhesion 
molecule 1*  F1S3J9_PIG 58 0.8±2.2 0.0±0.0 0.0 n/a n/a 
Kininogen-1* KNG1_PIG 48 20.6±15.8 14.8±11.8 0.7 0.450 0.625 
Lactadherin  MFGM_PIG 46 253.9±104.7 407.3±57.5 1.6 0.008 0.092 
Laminin subunit alpha-4 F1RZM4_PIG 164 75.8±28.8 74.4±31.8 1.0 0.933 0.950 
Laminin subunit beta-1 F1SAE9_PIG 199 246.4±69.2 265.6±65.1 1.1 0.604 0.773 
Laminin subunit beta-2 F1SPT5_PIG 179 39.4±46.5 39.7±31.1 1.0 0.987 0.987 
Laminin subunit gamma-1 F1S663_PIG 177 406.9±140.2 440.3±100.8 1.1 0.619 0.775 
Latent TGFβ-binding 
protein 1 F1S405_PIG 148 28.3±9.3 19.5±6.9 0.7 0.068 0.242 
Latent TGFβ-binding 
protein 2 F1S2T5_PIG 196 174.6±79.5 198.0±58.4 1.1 0.544 0.721 
Latent TGFβ-binding 
protein 4 LTBP4_PIG 112 38.5±26.7 35.6±14.9 0.9 0.811 0.872 
Leukocyte elastase 
inhibitor  ILEU_PIG 43 27.5±31.0 7.0±5.3 0.3 0.134 0.339 
Lumican F1SQ09_PIG 39 490.7±128.7 145.1±44.0 0.3 0.000 0.012 
Lysyl oxidase homolog 1 F1SIC9_PIG 65 68.5±29.0 63.0±19.0 0.9 0.687 0.799 
Macrophage capping 
protein F1SVB0_PIG 39 109.4±87.6 62.1±38.0 0.6 0.226 0.433 
Matrilin-4* F1SDQ7_PIG 69 0.5±1.2 0.7±1.9 1.5 n/a n/a 
Matrix Gla protein  MGP_PIG 12 27.1±5.8 61.9±31.1 2.3 0.025 0.163 
Matrix-remodeling-
associated protein 5 F1RZ07_PIG 308 47.9±48.7 13.7±8.9 0.3 0.114 0.305 
Metalloproteinase inhibitor 
1* TIMP1_PIG 23 0.4±0.9 0.0±0.0 0.0 n/a n/a 
Mimecan I3L9T6_PIG 25 108.2±29.8 96.8±26.8 0.9 0.467 0.642 
Myeloperoxidase K7GRV6_PIG 84 4.5±8.1 0.0±0.0 0.0 n/a n/a 
Nidogen-1  NID1_PIG 50 29.1±17.4 76.6±35.8 2.6 0.012 0.127 
Nidogen-2 F1SFF3_PIG 152 948.4±283.4 713.1±127.3 0.8 0.079 0.256 
Osteoclast-stimulating 
factor 1* OSTF1_PIG 24 13.8±11.9 6.3±5.4 0.5 0.166 0.350 
Papilin F1S3J7_PIG 141 0.1±0.2 0.7±1.8 9.3 n/a n/a 
Peptidyl-prolyl cis-trans 
isomerase A  PPIA_PIG 18 732.6±221.5 646.6±224.5 0.9 0.484 0.657 
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Periostin F1RS37_PIG 93 2380.0±652.6 1489.0±573.9 0.6 0.019 0.139 
Perlecan PGBM_PIG 365 3168.6±652.1 3467.1±535.4 1.1 0.368 0.581 
Peroxidasin homolog I3LDA4_PIG 164 13.3±8.3 31.7±10.6 2.4 0.004 0.071 
Pigment epithelium-
derived factor  Q0PM28_PIG 46 264.7±46.4 314.9±70.6 1.2 0.146 0.342 
Plasma glutamate 
carboxypeptidase* PGCP_PIG 52 2.3±3.2 1.3±1.7 0.6 n/a n/a 
Plasminogen  PLMN_PIG 91 272.3±106.8 514.1±199.6 1.9 0.019 0.139 
Podocan I3LEB7_PIG 72 60.1±38.7 23.4±10.0 0.4 0.047 0.203 
Procollagen C-
endopeptidase enhancer 1 I3LEE6_PIG 50 40.2±10.6 41.9±11.6 1.0 0.778 0.861 
Prolargin F1S6B4_PIG 43 451.1±102.9 351.1±138.2 0.8 0.153 0.342 
Prolow-density lipoprotein 
receptor-related protein 1  K9IVL7_PIG 505 30.4±26.2 20.5±7.4 0.7 0.372 0.581 
Properdin K7GQR1_PIG 51 57.9±29.3 117.1±61.8 2.0 0.049 0.203 
Prophenin and tritrpticin 
precursor  PF11_PIG 24 230.0±297.6 7.5±8.9 0.0 0.095 0.279 
Proteoglycan 4 I3L5Z3_PIG 149 0.9±1.5 0.0±0.0 0.0 n/a n/a 
Reticulon-3* RTN3_PIG 105 0.0±0.0 0.6±1.5 n/a n/a n/a 
RPE-spondin RPESP_PIG 32 1.1±3.0 1.9±3.3 1.6 n/a n/a 
Secreted frizzled-related 
protein 1 I3LB66_PIG 35 12.1±6.0 9.2±6.4 0.8 0.400 0.592 
Secreted frizzled-related 
protein 3* F1RYL4_PIG 36 3.3±3.6 2.5±1.1 0.8 0.591 0.766 
Secreted phosphoprotein 
24*  SPP24_PIG 23 0.0±0.0 12.4±9.1 n/a n/a n/a 
Serine protease HTRA1 F1SEH4_PIG 56 138.2±102.9 348.3±183.4 2.5 0.026 0.163 
Serotransferrin  TRFE_PIG 77 3167.4±2227.2 1765.1±729.6 0.6 0.156 0.342 
Serum amyloid P-
component  SAMP_PIG 26 3.2±6.3 14.2±14.9 4.4 n/a n/a 
SPARC  SPRC_PIG 34 128.6±37.6 154.1±75.8 1.2 0.448 0.625 
Spondin-1 SPON1_PIG 66 5.7±4.8 0.7±1.0 0.1 0.033 0.182 
Sulfhydryl oxidase  F1S682_PIG 81 19.2±11.1 11.8±6.2 0.6 0.154 0.342 
Superoxide dismutase 
[Cu-Zn]  Q007T6_PIG 26 236.2±133.9 155.7±49.9 0.7 0.176 0.364 
T-cadherin* A8D737_PIG 78 22.0±12.0 13.9±6.9 0.6 0.153 0.342 
Tenascin  TENA_PIG 191 861.4±309.9 1192.9±318.3 1.4 0.072 0.248 
Tetranectin F1SRC8_PIG 22 156.6±34.1 171.5±75.3 1.1 0.644 0.798 
TGFβ-induced protein ig-
h3  BGH3_PIG 74 64.8±20.5 55.1±13.0 0.9 0.317 0.532 
Thrombospondin-1 K7GPJ3_PIG 120 344.4±124.1 565.3±195.2 1.6 0.030 0.178 
Thrombospondin-4* F1RF28_PIG 104 8.9±7.9 33.3±26.4 3.7 0.051 0.203 
Translationally-controlled 
tumor protein* TCTP_PIG 20 50.9±23.5 49.1±19.5 1.0 0.874 0.914 
Tryptase  TRYT_PIG 30 0.1±0.3 0.0±0.0 0.0 n/a n/a 
Tubulointerstitial nephritis 
antigen-like F1SVA2_PIG 52 98.8±33.3 128.6±24.4 1.3 0.083 0.257 
Versican F1REZ2_PIG 369 1073.4±242.9 797.6±234.6 0.7 0.052 0.203 
Vitamin D-binding protein I3LN42_PIG 53 143.0±62.4 106.4±38.1 0.7 0.215 0.429 
Vitronectin  VTNC_PIG 53 419.9±72.3 1038.1±338.7 2.5 0.003 0.063 
von Willebrand factor A 
domain-containing protein 
1 F1RJE3_PIG 44 8.3±6.4 10.0±7.6 1.2 0.660 0.799 
WD repeat-containing 
protein 1  K9IVR7_PIG 66 288.7±36.1 297.6±112.3 1.0 0.848 0.895 
 
 
P values for differential expression between neointimal DES and BMS are based on unpaired Student’s t-tests 
with unequal variance (n=7 [BMS], n=7 [DES]). T-test was not performed if a protein was undetectable in the 
majority of samples from 1 of the 2 groups compared. Results in bold indicate P < 0.05. Values are average 
(Av) total ion current (TIC) x 106 ± standard deviation (SD). n/a denotes not applicable, FC denotes fold change. 
FDR denotes false discovery rate. The FDR threshold was set at 10%. Protein changes with P <0.05 and a 
FDR of <10% are highlighted in bold. Proteins only identified in the neointima, but not media are marked with*.
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Supplemental Table III. Extracellular proteins identified by proteomics in the media of stented porcine coronary arteries. 
 
 
  Bare-metal stent   Drug-eluting stent   
  Total ion current x 106 Av±SD   Total ion current x 106 Av±SD   
Identified Proteins UniProt ID BMS 1 BMS 3 BMS 7 BMS 28 
P 
BMS FDR DES 1 DES 3 DES 7 DES 28 
P 
DES FDR 
Adipocyte enhancer-binding 
protein 1 F1SSF7_PIG 0.3±0.5 0.2±0.3 1.6±1.3 1.1±0.5 0.136 0.326 0.1±0.2 0.0±0.0 1.0±0.9 6.2±4.8 0.046 0.140 
Aggrecan  F1SKR0_PIG 6.5±2.3 2.7±0.9 18.0±11.4 28.2±9.0 0.010 0.088 5.2±2.1 10.9±9.3 18.3±7.6 52.5±11.1 0.000 0.011 
Agrin  I3LGD9_PIG 5.7±2.5 5.4±2.8 8.7±1.1 9.4±1.7 0.112 0.310 5.7±3.3 5.2±3.5 8.8±1.3 6.2±1.6 0.400 0.523 
Alpha-2-HS-glycoprotein  FETUA_PIG 1.4±1.4 1.6±1.5 2.6±1.9 5.2±8.5 0.717 0.751 4.0±2.1 3.7±2.4 3.7±3.7 7.8±7.5 0.623 0.679 
Annexin A1  ANXA1_PIG 1.8±0.8 2.3±1.0 1.7±0.6 2.0±2.2 0.943 0.943 2.4±1.1 3.7±1.6 3.7±2.9 3.7±0.9 0.765 0.793 
Annexin A2  ANXA2_PIG 10.8±1.8 14.2±4.7 24.3±4.3 37.2±31.9 0.265 0.431 9.5±1.5 12.7±7.0 20.8±4.3 28.1±7.7 0.016 0.066 
Antithrombin-III  Q7M364_PIG 2.5±1.3 0.8±0.5 0.0±0.0 0.7±0.8 0.028 0.161 1.4±0.7 14.2±17.7 2.1±1.1 1.7±0.7 0.289 0.432 
Apolipoprotein A-I  APOA1_PIG 18.7±4.3 11.0±8.0 21.2±12.5 25.6±16.3 0.484 0.580 17.5±2.2 26.8±13.5 19.1±13.2 24.8±10.0 0.686 0.732 
Apolipoprotein A-IV  APOA4_PIG 0.1±0.1 0.0±0.0 0.1±0.1 0.4±0.6 0.394 0.536 0.0±0.1 1.7±1.1 0.4±0.5 0.5±0.3 0.053 0.142 
Apolipoprotein C-III  APOC3_PIG 4.4±2.5 2.3±1.4 0.6±0.6 0.7±0.7 0.049 0.231 4.3±1.7 5.6±2.9 0.5±0.6 0.8±0.4 0.016 0.066 
Apolipoprotein E  APOE_PIG 15.7±4.0 11.3±7.0 1.8±1.7 1.6±0.7 0.006 0.077 8.9±4.2 82.2±70.2 8.9±6.2 1.9±2.4 0.071 0.156 
Apolipoprotein H  I3LGN5_PIG 21.7±6.2 20.3±5.4 18.7±2.7 29.4±18.3 0.603 0.657 26.7±5.1 36.6±27.2 29.3±14.7 59.5±10.6 0.139 0.260 
Apolipoprotein R  APOR_PIG 1.6±1.1 1.0±0.3 0.8±0.8 0.3±0.3 0.213 0.395 2.6±1.6 6.8±2.7 0.9±0.8 0.5±0.5 0.006 0.034 
Asporin  F1SUE4_PIG 78.2±16.2 62.0±11.9 86.2±17.1 150.3±37.5 0.007 0.077 77.5±16.5 81.7±37.1 90.1±30.2 157.3±43.8 0.059 0.142 
Biglycan  K7GP55_PIG 796.0±130.8 648.1±186.6 952.7±42.3 1503.4±443.4 0.014 0.104 748.6±200.3 750.0±367.0 1002.9±236.7 1972.6±202.2 0.001 0.011 
Carboxypeptidase-like protein 
X2 F1SEC6_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.4±0.2 n/a n/a 
Cathepsin D  Q4U1U3_PIG 1.6±0.5 1.9±0.3 7.2±4.8 8.8±13.1 0.523 0.604 1.1±1.5 2.3±1.6 4.1±3.6 3.7±1.8 0.412 0.523 
Cathepsin G  F1SGS1_PIG 0.5±0.3 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 0.8±0.8 0.8±0.7 0.1±0.1 0.0±0.0 0.201 0.341 
Chitinase-3-like protein 1  CH3L1_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.3±0.5 n/a n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 
Chondroitin sulfate 
proteoglycan 4* CSPG4_HUMAN 0.1±0.1 0.0±0.0 0.3±0.5 0.0±0.0 0.415 0.546 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 
Clusterin  CLUS_PIG 98.2±51.7 59.8±17.0 45.6±16.8 16.4±10.7 0.048 0.231 59.0±19.6 273.4±202.6 61.0±24.0 21.2±10.8 0.060 0.142 
Collagen alpha-1 (I) CO1A1_PIG 2915.1±375.6 2913.2±993.1 4118.5±199.0 2622.2±1399.4 0.244 0.419 2749.1±797.9 1973.1±1213.2 3353.0±487.7 3996.0±273.1 0.062 0.142 
Collagen alpha-1 (II)* I3LSV6_PIG 108.4±22.4 127.9±54.4 149.6±3.8 68.4±34.1 0.090 0.276 100.9±39.9 77.0±38.5 122.7±62.7 116.6±15.0 0.584 0.669 
Collagen alpha-1 (III)  F1RYI8_PIG 332.8±111.3 571.8±520.0 454.4±127.6 472.3±201.4 0.797 0.807 302.2±59.7 185.0±119.2 318.7±83.5 480.3±67.1 0.019 0.072 
Collagen alpha-1 (IV) M3V819_PIG 3.1±2.1 5.7±1.9 7.5±2.2 8.8±3.3 0.091 0.276 2.5±0.4 4.2±2.5 6.6±0.9 4.3±1.2 0.055 0.142 
Collagen alpha-1 (V)  F1S021_PIG 81.8±19.0 108.4±42.0 181.5±36.4 174.3±88.5 0.128 0.325 82.2±11.7 109.9±66.9 126.0±20.7 251.3±25.0 0.003 0.019 
Collagen alpha-1 (VI) CO6A1_PIG 4.5±1.2 3.6±3.9 2.0±0.4 10.3±8.4 0.221 0.395 4.8±2.2 6.2±5.1 2.6±2.9 1.8±0.3 0.371 0.507 
Collagen alpha-1 (VIII)  F1SKX7_PIG 0.2±0.3 0.2±0.4 1.5±0.6 0.5±0.4 0.013 0.104 0.1±0.2 0.4±0.4 1.8±0.9 3.2±1.0 0.002 0.019 
Collagen alpha-1 (XI)  F1S571_PIG 48.9±9.7 50.3±22.3 111.5±27.7 103.7±54.7 0.088 0.276 45.9±2.4 62.4±36.9 60.7±17.8 190.8±17.9 0.000 0.006 
Collagen alpha-1 (XII) COCA1_PIG 7.1±0.5 3.4±2.9 17.2±16.6 46.9±52.0 0.273 0.438 5.7±0.7 3.8±1.8 14.2±10.6 53.7±15.8 0.001 0.011 
Collagen alpha-1 (XV) COFA1_PIG 3.2±1.0 2.5±0.9 9.0±2.7 9.5±4.8 0.028 0.161 2.3±1.8 2.1±1.2 10.0±2.2 14.1±3.8 0.001 0.011 
Collagen alpha-1 (XVIII) COIA1_PIG 10.5±3.5 12.3±7.3 11.4±1.1 6.7±1.3 0.420 0.546 8.5±3.5 12.9±5.7 12.2±4.8 1.6±0.3 0.035 0.115 
Collagen alpha-1 (XX) COKA1_PIG  14.6±12.5 5.7±4.3 22.3±9.2 60.8±43.8 0.081 0.276 8.2±2.6 4.0±2.6 24.8±9.2 22.2±2.9 0.003 0.019 
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Collagen alpha-2 (I)  F1SFA7_PIG 2540.2±281.6 2097.8±569.3 3114.0±344.6 2616.7±1337.8 0.482 0.580 2441.6±563.3 1949.6±1173.6 2966.9±215.8 4329.5±613.6 0.019 0.072 
Collagen alpha-2 (IV)  F1RLL9_PIG 3.1±1.8 6.9±2.4 7.2±4.2 7.8±0.2 0.184 0.365 1.9±0.6 4.1±3.7 8.4±3.2 2.1±0.4 0.038 0.120 
Collagen alpha-2 (V)  Q59IP2_PIG 84.2±45.2 108.2±40.4 172.3±73.6 173.7±84.4 0.281 0.444 87.0±14.8 91.2±57.0 156.5±6.4 200.7±119.1 0.188 0.328 
Collagen alpha-2 (VI)  I3LQ84_PIG 13.4±3.9 15.3±15.9 7.1±1.6 41.7±41.5 0.309 0.461 14.8±5.6 23.3±24.5 10.3±4.8 8.5±3.2 0.534 0.630 
Collagen alpha-2 (XI)* A5D9K7_PIG 23.6±4.3 36.2±12.2 49.2±10.5 37.8±22.7 0.250 0.420 22.2±5.9 32.8±16.0 30.3±10.1 52.3±10.3 0.055 0.142 
Collagen alpha-3 (V)  Q59IP1_PIG 1.1±0.7 1.6±1.2 1.9±0.8 5.8±5.3 0.220 0.395 1.2±0.7 1.9±2.1 2.1±1.0 3.2±1.3 0.402 0.523 
Collagen alpha-3 (VI)  I3LUR7_PIG 42.7±11.3 38.2±40.2 16.2±6.8 92.4±98.5 0.411 0.546 32.6±15.3 41.5±39.4 21.3±16.8 18.4±11.3 0.624 0.679 
Collagen alpha-6 (VI) CO6A6_PIG 0.0±0.0 0.0±0.0 0.0±0.0 14.1±24.5 n/a n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 
Complement C3  CO3_PIG 4.3±1.1 0.1±0.2 0.6±0.3 1.8±3.1 0.063 0.249 3.3±1.4 14.2±20.9 1.4±1.6 0.4±0.6 0.405 0.523 
Complement component C9  A0SEG9_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 0.0±0.0 1.0±1.7 0.0±0.0 0.0±0.0 n/a n/a 
Connective tissue growth 
factor  CTGF_PIG 0.4±0.3 0.3±0.5 0.7±0.6 0.0±0.0 0.308 0.461 0.8±0.4 0.4±0.3 0.7±0.4 0.1±0.2 0.212 0.345 
Decorin  PGS2_PIG 581.1±67.5 418.8±208.1 411.1±91.6 1166.4±602.8 0.064 0.249 610.5±85.3 554.8±357.0 441.8±67.1 1145.6±50.6 0.008 0.039 
Dermatopontin  DERM_PIG 52.5±13.7 43.6±33.0 45.1±3.3 126.2±69.7 0.090 0.276 64.5±12.2 59.9±38.4 80.7±23.7 150.5±20.2 0.008 0.039 
Dystroglycan  I3LD20_PIG 1.2±1.1 0.6±0.5 0.7±0.2 0.7±0.6 0.729 0.756 0.9±0.6 0.8±1.1 0.6±0.2 0.8±0.5 0.945 0.953 
EMILIN-1 F1SDQ5_PIG 6.1±3.2 8.3±2.1 7.9±2.5 10.7±2.4 0.261 0.431 5.6±1.8 6.4±2.8 9.1±1.0 8.8±3.8 0.316 0.461 
Fibrillin-1  FBN1_PIG 0.2±0.4 0.8±1.4 0.0±0.0 0.0±0.0 0.519 0.604 0.2±0.3 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 
Fibrinogen beta chain  F1RX37_PIG 1240.6±374.6 268.9±219.0 49.0±38.0 3.3±0.7 0.000 0.025 1240.6±892.3 2814.7±3732.6 77.6±53.1 53.8±46.6 0.317 0.461 
Fibrinogen gamma chain  F1RX35_PIG 1124.9±400.8 267.0±197.3 43.8±31.0 8.0±0.7 0.001 0.025 994.9±674.2 2014.6±2519.2 69.7±42.6 39.7±31.3 0.277 0.431 
Fibromodulin  F1S6B5_PIG 144.8±77.4 73.5±29.1 200.7±36.9 299.2±28.4 0.002 0.046 135.1±50.9 62.4±47.7 185.0±36.5 598.9±175.3 0.001 0.011 
Fibronectin  F1SS24_PIG 557.8±157.1 983.5±206.3 1109.9±420.0 503.9±198.9 0.055 0.241 527.0±248.9 1237.2±357.0 870.3±360.6 925.0±188.5 0.104 0.205 
Fibronectin type III domain-
containing protein 1  F1SB59_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.2±0.2 n/a n/a 0.0±0.0 0.0±0.0 0.0±0.0 1.0±1.5 n/a n/a 
Fibulin-1  F1SM61_PIG 0.3±0.1 0.0±0.1 0.4±0.3 0.4±0.5 0.438 0.562 0.1±0.2 0.3±0.6 0.4±0.2 2.0±1.5 0.077 0.160 
Fibulin-2 FBLN2_PIG 0.0±0.0 0.2±0.3 0.3±0.3 0.3±0.4 0.634 0.677 0.0±0.0 0.0±0.0 1.5±1.4 4.0±2.0 0.011 0.052 
Fibulin-3 F8SIP2_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.2±0.3 n/a n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 
Fibulin-5  F1SD87_PIG 11.3±1.8 4.4±1.7 7.6±1.1 17.7±13.6 0.185 0.365 9.5±2.7 7.4±3.1 7.3±3.9 7.8±1.5 0.772 0.793 
Galectin-1  LEG1_PIG 16.2±4.0 23.5±12.5 40.8±10.8 30.3±8.2 0.062 0.249 23.7±5.0 14.6±10.3 34.3±3.1 25.7±8.6 0.062 0.142 
Galectin-3 A3EX84_PIG 0.1±0.1 0.2±0.3 1.0±0.2 3.9±6.0 0.421 0.546 0.2±0.2 0.1±0.1 0.5±0.4 1.1±0.2 0.002 0.017 
Galectin-3-binding protein M3V7X9_PIG 0.4±0.8 2.4±3.2 4.1±1.5 0.7±0.6 0.127 0.325 0.0±0.0 1.3±2.0 1.8±1.5 1.3±0.9 0.475 0.579 
Gelsolin GELS_PIG 217.8±17.2 129.6±51.0 160.6±18.1 179.7±80.3 0.246 0.419 227.7±68.3 150.1±78.2 194.7±35.8 155.4±18.4 0.345 0.495 
Hyaluronan and proteoglycan 
link protein 1  HPLN1_PIG 2.6±2.2 3.5±2.7 7.1±2.5 3.4±0.7 0.128 0.325 4.4±2.5 9.6±2.5 10.9±6.5 0.9±0.8 0.036 0.116 
Hyaluronan and proteoglycan 
link protein 3* HPLN3_HUMAN 0.2±0.3 0.4±0.8 0.6±0.7 0.0±0.0 0.552 0.613 0.7±0.6 0.6±1.0 1.0±1.1 0.1±0.2 0.604 0.677 
Hyaluronan and proteoglycan 
link protein 4* HPLN4_HUMAN 0.0±0.0 0.0±0.0 0.2±0.3 0.0±0.0 n/a n/a 0.0±0.0 0.6±0.6 0.0±0.0 0.0±0.0 n/a n/a 
Insulin-like growth factor-
binding protein 7  C7EDN1_PIG 2.0±1.2 4.3±3.8 22.3±2.8 11.1±9.9 0.008 0.080 2.1±2.3 1.5±1.7 21.0±7.4 8.8±0.8 0.001 0.011 
Inter-alpha-trypsin inhibitor 
heavy chain H2  ITIH2_PIG 8.4±3.7 4.5±2.1 3.6±2.2 4.1±1.6 0.163 0.356 6.8±1.5 6.4±3.9 5.7±1.8 6.1±5.2 0.985 0.985 
Lactadherin  MFGM_PIG 7.9±4.8 11.7±5.7 17.8±9.7 19.1±15.3 0.499 0.591 4.8±3.8 9.3±7.2 19.7±5.5 6.1±0.6 0.022 0.081 
Laminin subunit alpha-4  F1RZM4_PIG 6.2±1.5 2.1±1.5 3.5±1.5 11.2±3.5 0.004 0.065 6.7±4.6 3.9±2.2 3.6±3.9 3.9±1.5 0.655 0.705 
Laminin subunit beta-1  F1SAE9_PIG 2.8±1.3 1.4±1.2 6.2±4.7 9.4±1.0 0.020 0.127 1.6±1.9 1.4±1.0 4.6±2.7 2.0±1.2 0.188 0.328 
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Laminin subunit beta-2  F1SPT5_PIG 8.8±2.3 8.1±0.2 7.1±0.9 8.7±1.3 0.462 0.577 6.2±3.7 11.0±2.8 8.3±5.3 4.3±1.9 0.205 0.343 
Laminin subunit gamma-1  F1S663_PIG 41.7±11.2 35.9±1.9 38.7±5.3 47.8±8.8 0.330 0.477 36.6±21.7 39.7±6.9 42.7±18.6 16.7±4.9 0.213 0.345 
Latent-TGFß-binding protein 1  F1S405_PIG 0.7±0.7 0.4±0.1 0.3±0.2 0.2±0.2 0.526 0.604 0.3±0.1 0.5±0.5 0.6±0.5 0.0±0.0 0.285 0.432 
Latent-TGFß-binding protein 
2  F1S2T5_PIG 2.5±1.3 2.9±2.0 5.5±1.0 2.7±2.4 0.213 0.395 2.4±1.1 2.4±1.8 10.2±0.8 9.1±1.6 0.000 0.006 
Latent-TGFß-binding protein 4 LTBP4_PIG 3.7±1.9 0.1±0.1 0.0±0.0 4.9±5.6 0.177 0.365 5.5±1.7 1.1±1.7 1.4±0.6 2.8±2.9 0.074 0.156 
Leukocyte elastase inhibitor  ILEU_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.1±0.2 n/a n/a 1.0±0.4 1.6±2.8 0.0±0.0 0.0±0.0 0.463 0.577 
Lipoprotein lipase* LIPL_PIG 1.8±0.4 1.2±2.0 0.0±0.0 0.0±0.0 0.150 0.335 1.4±0.6 6.1±2.7 3.3±2.1 0.0±0.0 0.012 0.052 
Lumican  F1SQ09_PIG 288.9±36.6 204.3±53.9 312.6±49.2 431.5±212.7 0.188 0.365 257.0±73.7 277.8±152.9 282.2±61.7 405.1±59.0 0.286 0.432 
Lysyl oxidase homolog 1 F1SIC9_PIG 5.7±5.2 0.7±0.6 3.9±1.2 7.8±3.3 0.110 0.310 6.2±7.8 2.0±1.7 6.6±4.9 11.3±1.1 0.195 0.336 
Macrophage-capping protein  F1SVB0_PIG 0.0±0.0 0.0±0.0 0.1±0.1 0.6±1.0 n/a n/a 0.1±0.1 0.0±0.0 0.2±0.2 0.4±0.2 0.060 0.142 
Matrix Gla protein  MGP_PIG 1.2±0.4 1.7±0.1 2.5±1.1 1.3±0.8 0.149 0.335 1.3±0.7 1.3±0.7 2.8±0.3 1.4±0.5 0.035 0.115 
Matrix-remodeling-associated 
protein 5  F1RZ07_PIG 0.3±0.4 6.3±5.4 6.5±9.2 7.4±9.7 0.631 0.677 0.1±0.2 3.9±1.9 7.3±9.9 11.5±5.5 0.175 0.321 
Mimecan  I3L9T6_PIG 426.0±40.0 220.5±139.0 255.7±34.2 495.6±304.8 0.220 0.395 389.9±27.1 292.7±193.6 283.7±7.3 581.3±152.7 0.061 0.142 
Myeloperoxidase  K7GRV6_PIG 1.1±1.1 0.3±0.5 0.0±0.0 0.7±1.2 0.479 0.580 2.6±2.9 4.4±7.5 0.0±0.0 0.0±0.0 0.494 0.589 
Nidogen-1 NID1_PIG 1.5±0.8 2.2±2.2 4.3±1.7 6.1±2.5 0.070 0.255 2.0±0.7 3.8±2.2 5.3±2.6 8.1±2.7 0.049 0.142 
Nidogen-2  F1SFF3_PIG 109.6±14.8 137.7±31.0 155.9±5.2 173.2±56.0 0.187 0.365 104.0±32.6 157.8±56.4 161.3±12.5 96.8±25.8 0.109 0.211 
Papilin  F1S3J7_PIG 0.6±1.0 0.3±0.6 0.2±0.2 0.1±0.2 0.800 0.807 0.6±0.5 0.7±0.5 0.3±0.3 0.0±0.0 0.218 0.349 
Pentraxin-related protein 
PTX3* F1SJM0_PIG 0.9±0.8 1.2±1.1 0.0±0.0 0.1±0.1 0.138 0.326 0.8±0.3 0.5±0.9 1.4±1.1 0.0±0.0 0.234 0.369 
Peptidyl-prolyl cis-trans 
isomerase A  PPIA_PIG 2.2±1.0 1.5±0.7 4.3±1.5 6.2±8.1 0.536 0.604 3.8±1.8 3.6±2.5 5.8±4.0 7.3±2.8 0.385 0.519 
Periostin F1RS37_PIG 2.5±2.3 22.6±19.5 100.3±69.3 148.3±199.7 0.361 0.505 0.5±0.5 6.8±7.0 86.6±62.7 287.5±33.2 0.000 0.003 
Perlecan PGBM_PIG 210.9±42.8 188.9±59.9 245.7±21.6 384.9±98.0 0.019 0.127 215.7±38.4 237.8±121.6 321.6±78.5 336.2±111.9 0.359 0.506 
Peroxidasin homolog  I3LDA4_PIG 0.0±0.0 0.3±0.3 0.2±0.1 0.2±0.4 0.565 0.622 0.0±0.0 0.0±0.0 0.1±0.2 0.0±0.0 n/a n/a 
Pigment epithelium-derived 
factor  Q0PM28_PIG 0.4±0.5 0.5±0.9 2.2±0.9 0.9±1.2 0.134 0.326 0.3±0.5 0.2±0.3 3.3±2.7 1.9±1.3 0.101 0.203 
Plasminogen  PLMN_PIG 57.8±54.2 79.7±55.9 10.7±5.6 2.1±1.8 0.114 0.310 34.6±16.9 146.3±54.8 11.2±6.5 2.6±1.8 0.001 0.011 
Podocan  I3LEB7_PIG 0.8±0.4 0.1±0.2 1.1±0.8 2.8±1.6 0.030 0.163 0.6±0.7 0.5±0.3 0.9±1.1 1.0±0.8 0.888 0.905 
Procollagen C-endopeptidase 
enchancer 1  I3LEE6_PIG 0.2±0.1 0.1±0.1 0.8±0.5 0.7±0.3 0.069 0.255 0.2±0.2 0.1±0.1 2.7±3.8 1.1±0.5 0.366 0.506 
Prolargin  F1S6B4_PIG 269.7±21.2 200.2±42.2 300.6±54.5 608.6±187.3 0.005 0.065 263.7±49.7 255.3±109.7 341.3±134.5 995.5±337.7 0.004 0.024 
Prolow-density lipoprotein 
receptor-related protein 1  K9IVL7_PIG 1.1±0.3 1.4±1.6 3.5±3.5 4.2±2.1 0.295 0.454 1.4±1.2 0.7±0.5 3.6±2.8 4.5±1.2 0.066 0.147 
Properdin  K7GQR1_PIG 0.7±0.6 0.3±0.3 0.0±0.0 0.3±0.3 0.228 0.401 0.6±0.7 0.6±0.7 0.3±0.5 0.2±0.1 0.749 0.783 
Prophenin and tritrpticin 
precursor  PF11_PIG 63.9±15.1 16.9±10.5 2.1±1.0 8.0±13.4 0.001 0.025 94.1±47.6 186.5±155.5 9.8±2.0 1.1±1.6 0.074 0.156 
Proteoglycan 4 I3L5Z3_PIG 0.5±0.2 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 0.0±0.1 0.1±0.2 0.0±0.0 0.0±0.0 0.554 0.646 
RPE-spondin RPESP_PIG 4.8±2.1 7.9±7.7 5.8±3.3 1.5±1.3 0.393 0.536 9.0±9.3 4.7±2.9 9.3±5.6 2.4±0.4 0.415 0.523 
Secreted frizzled-related 
protein 1  I3LB66_PIG 0.0±0.0 0.0±0.0 0.4±0.6 0.9±0.9 0.183 0.365 0.0±0.0 0.0±0.0 0.2±0.3 0.7±0.0 0.001 0.011 
Serine protease HTRA1  F1SEH4_PIG 7.0±1.7 10.8±4.9 46.7±13.0 45.6±41.4 0.100 0.296 5.5±2.7 6.5±3.8 37.4±17.4 37.2±21.0 0.029 0.101 
Serotransferrin  TRFE_PIG 0.4±0.4 2.3±0.7 1.7±1.8 3.2±5.6 0.710 0.751 3.0±2.3 6.0±2.7 1.6±2.0 6.6±9.7 0.624 0.679 
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Serum amyloid P-component  SAMP_PIG 0.1±0.1 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 0.1±0.1 0.0±0.0 0.0±0.0 0.0±0.1 0.713 0.753 
SPARC  SPRC_PIG 0.3±0.6 3.6±1.3 3.5±1.4 0.8±1.0 0.010 0.088 0.4±0.7 0.5±0.7 3.2±1.9 4.7±1.2 0.008 0.039 
Spondin-1 SPON1_PIG 0.0±0.0 0.1±0.1 0.5±0.5 0.4±0.7 0.449 0.569 0.1±0.1 0.1±0.2 0.5±0.3 0.9±0.8 0.187 0.328 
Sulfhydryl oxidase  F1S682_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 0.0±0.0 0.1±0.2 0.0±0.0 0.0±0.0 n/a n/a 
Superoxide dismutase [Cu-Zn]  Q007T6_PIG 1.1±0.4 0.2±0.2 1.6±0.6 1.3±0.7 0.042 0.215 1.8±1.5 0.2±0.2 1.3±0.3 2.1±0.6 0.098 0.200 
Target of Nesh-SH3* F1SL03_PIG 3.1±1.9 0.9±1.5 1.3±2.0 4.1±4.5 0.466 0.577 4.3±2.0 0.8±0.8 3.3±1.0 13.5±5.4 0.004 0.024 
Tenascin  TENA_PIG 64.2±20.0 52.4±13.9 257.6±39.4 168.2±84.9 0.003 0.046 44.9±12.4 82.6±47.7 168.9±41.0 106.5±33.4 0.017 0.070 
Tenascin XB*  A5A8W4_PIG 5.5±2.3 4.4±7.1 3.4±4.8 9.4±11.0 0.747 0.769 5.7±4.1 5.9±5.4 1.8±1.4 6.1±5.3 0.586 0.669 
Tetranectin  F1SRC8_PIG 1.6±0.5 0.9±0.8 2.5±2.0 2.3±0.4 0.324 0.477 1.7±0.8 2.2±2.0 3.5±2.6 6.7±2.1 0.059 0.142 
TGFß-1* TGFB1_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 0.0±0.0 0.2±0.3 0.0±0.0 0.0±0.0 n/a n/a 
TGFß-3* K7GSJ9_PIG 0.0±0.0 0.0±0.0 0.0±0.0 0.0±0.0 n/a n/a 0.0±0.0 0.0±0.0 0.0±0.0 0.6±0.9 n/a n/a 
TGFß-induced protein ig-h3  BGH3_PIG 19.5±5.0 15.1±11.9 9.5±4.3 27.0±17.6 0.333 0.477 9.0±3.3 15.7±8.3 22.6±19.7 8.6±4.8 0.415 0.523 
Throbospondin-1 K7GPJ3_PIG 5.8±2.3 4.2±1.7 7.2±2.1 2.7±0.9 0.073 0.257 4.3±0.9 6.3±2.1 7.1±1.8 6.1±3.2 0.491 0.589 
Tryptase  TRYT_PIG 0.0±0.0 0.0±0.0 0.0±0.0 3.8±6.6 n/a n/a 0.0±0.0 0.0±0.1 0.0±0.0 0.4±0.7 0.475 0.579 
Tubulointerstitial nephritis 
antigen-like  F1SVA2_PIG 83.0±10.1 56.6±25.4 53.2±6.7 65.1±9.5 0.142 0.329 71.7±13.9 67.8±36.6 69.5±11.8 43.5±5.7 0.364 0.506 
Versican  F1REZ2_PIG 70.2±5.8 103.0±18.5 153.5±7.9 148.5±26.1 0.001 0.025 112.2±54.7 81.1±31.6 231.4±38.8 398.1±137.4 0.004 0.025 
Vitamin D-binding protein  I3LN42_PIG 8.7±5.6 1.3±1.0 2.7±1.1 1.4±1.8 0.051 0.231 5.3±1.1 9.0±5.5 2.8±1.9 1.4±1.0 0.062 0.142 
Vitronectin  VTNC_PIG 298.1±250.1 239.7±90.3 148.2±65.3 87.3±94.7 0.352 0.498 202.6±40.6 694.9±156.0 235.4±154.0 82.8±48.1 0.001 0.011 
von Willebrand factor A 
domain-containing protein 1  F1RJE3_PIG 17.6±8.1 8.6±3.6 10.6±3.4 14.5±6.4 0.294 0.454 18.7±5.6 11.7±6.0 14.6±4.6 7.3±4.4 0.129 0.245 
WD repeat-containing protein 
1  K9IVR7_PIG 0.0±0.0 0.1±0.2 0.1±0.1 0.1±0.2 0.537 0.604 0.0±0.0 0.0±0.0 0.0±0.1 0.0±0.1 0.595 0.673 
 
 
P values for changes in BM or DES at different time-points were identified by one-way ANOVA (BMS: n=3 [BMS1/3/7/28], 1-way ANOVA; DES: n=3 [DES 1/3/7/28], 1-
way ANOVA). ANOVA was not applied if a protein was detected at only a single time point. Results in bold indicate P < 0.05. Values are average (Av) total ion current 
(TIC) x 106 ± standard deviation (SD). n/a denotes not applicable. FDR denotes false discovery rate. The FDR threshold was set at 10%. Protein changes with P <0.05 
and a FDR of <10% are highlighted in bold.  Proteins only identified in the media, but not neointima are marked with*. 
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Supplemental Table IV. Extracellular proteins identified by proteomics in the media of balloon 
dilated porcine coronary arteries. 
 
  Balloon angioplasty 
Total ion current x 106 Av±SD   
Identified Proteins UniProt ID BA early BA late 
FC 
late/early 
P      
BA FDR 
Adipocyte enhancer-binding 
protein 1 
F1SSF7_PIG 0.9±0.6 2.0±1.2 2.1 0.258 0.519 
Aggrecan  F1SKR0_PIG 5.3±3.0 17.3±10.7 3.3 0.187 0.431 
Agrin  I3LGD9_PIG 5.6±4.0 9.9±1.1 1.8 0.118 0.403 
Alpha-2-HS-glycoprotein  FETUA_PIG 3.7±2.2 1.9±1.4 0.5 0.232 0.492 
Annexin A1  ANXA1_PIG 3.1±0.8 0.5±0.2 0.2 0.005 0.217 
Annexin A2  ANXA2_PIG 14.2±10.5 14.9±2.9 1.1 0.898 0.951 
Antithrombin-III  Q7M364_PIG 2.5±1.8 0.3±0.5 0.1 n/a n/a 
Apolipoprotein A-I  APOA1_PIG 19.5±7.7 12.7±5.6 0.7 0.231 0.492 
Apolipoprotein A-IV  APOA4_PIG 0.0±0.0 0.1±0.1 n/a n/a n/a 
Apolipoprotein C-III  APOC3_PIG 6.5±3.9 0.2±0.4 0.0 0.048 0.301 
Apolipoprotein E  APOE_PIG 26.2±20.3 1.2±0.3 0.0 n/a n/a 
Apolipoprotein H  I3LGN5_PIG 23.1±4.4 19.5±8.5 0.8 0.551 0.720 
Apolipoprotein R  APOR_PIG 1.9±2.3 0.0±0.0 0.0 n/a n/a 
Asporin  F1SUE4_PIG 61.0±14.8 87.4±40.2 1.4 0.375 0.565 
Biglycan  K7GP55_PIG 659.9±210.4 971.4±110.9 1.5 0.056 0.301 
Carboxypeptidase-like protein 
X2 
F1SEC6_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
Cathepsin D  Q4U1U3_PIG 3.6±3.7 3.2±1.8 0.9 0.852 0.925 
Cathepsin G  F1SGS1_PIG 0.7±0.9 0.0±0.0 0.0 n/a n/a 
Chitinase-3-like protein 1  CH3L1_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
Chondroitin sulfate proteoglycan 
4* 
CSPG4_HUMAN 0.1±0.2 0.0±0.0 0.0 n/a n/a 
Clusterin  CLUS_PIG 95.9±46.7 19.7±8.5 0.2 0.044 0.301 
Collagen alpha-1 (I) CO1A1_PIG 2055.2±391.6 2088.2±468.7 1.0 0.926 0.958 
Collagen alpha-1 (II)* I3LSV6_PIG 82.5±12.5 67.2±16.1 0.8 0.248 0.514 
Collagen alpha-1 (III)  F1RYI8_PIG 252.0±85.1 431.9±112.0 1.7 0.087 0.384 
Collagen alpha-1 (IV) M3V819_PIG 4.3±2.7 5.2±1.7 1.2 0.628 0.778 
Collagen alpha-1 (V)  F1S021_PIG 75.2±29.8 96.9±37.1 1.3 0.453 0.640 
Collagen alpha-1 (VI) CO6A1_PIG 6.2±4.7 7.9±6.9 1.3 0.746 0.851 
Collagen alpha-1 (VIII)  F1SKX7_PIG 0.2±0.4 0.2±0.3 1.1 n/a n/a 
Collagen alpha-1 (XI)  F1S571_PIG 42.1±14.8 56.5±23.0 1.3 0.408 0.595 
Collagen alpha-1 (XII) COCA1_PIG 6.1±2.5 3.4±3.6 0.6 0.338 0.548 
Collagen alpha-1 (XV) COFA1_PIG 4.4±3.8 6.8±4.6 1.6 0.491 0.672 
Collagen alpha-1 (XVIII) COIA1_PIG 10.6±4.7 10.5±1.4 1.0 0.990 0.990 
Collagen alpha-1 (XX) COKA1_PIG  12.5±4.4 21.3±4.4 1.7 0.053 0.301 
Collagen alpha-2 (I)  F1SFA7_PIG 1819.5±446.0 2184.2±434.5 1.2 0.332 0.548 
Collagen alpha-2 (IV)  F1RLL9_PIG 5.4±6.5 5.6±2.6 1.0 0.961 0.972 
Collagen alpha-2 (V)  Q59IP2_PIG 75.8±40.3 84.1±59.3 1.1 0.846 0.925 
Collagen alpha-2 (VI)  I3LQ84_PIG 24.5±16.6 31.7±22.6 1.3 0.669 0.804 
Collagen alpha-2 (XI)* A5D9K7_PIG 24.6±9.4 25.0±7.5 1.0 0.951 0.972 
Collagen alpha-3 (V)  Q59IP1_PIG 0.6±0.4 1.2±0.9 2.0 0.338 0.548 
Collagen alpha-3 (VI)  I3LUR7_PIG 58.0±38.7 63.2±66.2 1.1 0.911 0.953 
Collagen alpha-6 (VI) CO6A6_PIG 0.2±0.3 0.0±0.0 0.0 n/a n/a 
Complement C3  CO3_PIG 12.3±8.9 1.8±2.1 0.1 0.097 0.384 
Complement component C9  A0SEG9_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
Connective tissue growth factor  CTGF_PIG 0.2±0.2 0.0±0.0 0.0 n/a n/a 
Decorin  PGS2_PIG 369.9±68.6 569.0±248.3 1.5 0.298 0.548 
Dermatopontin  DERM_PIG 36.2±8.6 74.7±13.9 2.1 0.022 0.288 
Dystroglycan  I3LD20_PIG 0.5±0.3 2.2±0.6 4.5 0.026 0.288 
EMILIN-1 F1SDQ5_PIG 9.4±4.2 14.5±3.6 1.5 0.148 0.420 
Fibrillin-1  FBN1_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
Fibrinogen beta chain  F1RX37_PIG 1514.5±1633.6 17.6±25.7 0.0 0.164 0.429 
Fibrinogen gamma chain  F1RX35_PIG 1214.6±1333.0 16.2±19.1 0.0 0.170 0.429 
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Fibromodulin  F1S6B5_PIG 76.2±40.4 273.4±67.2 3.6 0.019 0.288 
Fibronectin  F1SS24_PIG 996.9±285.9 314.4±116.2 0.3 0.011 0.253 
Fibronectin type III domain-
containing protein 1  
F1SB59_PIG 0.0±0.0 0.0±0.1 n/a n/a n/a 
Fibulin-1  F1SM61_PIG 0.6±0.4 0.3±0.3 0.4 0.269 0.519 
Fibulin-2 FBLN2_PIG 0.2±0.3 0.2±0.4 1.1 n/a n/a 
Fibulin-3 F8SIP2_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
Fibulin-5  F1SD87_PIG 10.0±5.2 14.0±8.2 1.4 0.511 0.689 
Galectin-1  LEG1_PIG 22.8±13.4 44.5±6.0 2.0 0.041 0.301 
Galectin-3 A3EX84_PIG 0.1±0.2 0.2±0.1 2.0 n/a n/a 
Galectin-3-binding protein M3V7X9_PIG 4.7±7.0 0.0±0.0 0.0 n/a n/a 
Gelsolin GELS_PIG 164.9±7.5 250.3±39.5 1.5 0.061 0.301 
Hyaluronan and proteoglycan 
link protein 1  
HPLN1_PIG 6.1±3.8 9.8±4.3 1.6 0.302 0.548 
Hyaluronan and proteoglycan 
link protein 3* 
HPLN3_HUMAN 1.6±0.7 0.8±1.1 0.5 0.367 0.565 
Hyaluronan and proteoglycan 
link protein 4* 
HPLN4_HUMAN 0.3±0.6 0.0±0.0 0.0 n/a n/a 
Insulin-like growth factor-binding 
protein 7  
C7EDN1_PIG 2.7±1.7 6.4±5.0 2.4 0.329 0.548 
Inter-alpha-trypsin inhibitor 
heavy chain H2  
ITIH2_PIG 7.2±1.4 2.1±1.6 0.3 0.011 0.253 
Lactadherin  MFGM_PIG 13.5±7.6 11.8±2.5 0.9 0.686 0.815 
Laminin subunit alpha-4  F1RZM4_PIG 6.5±4.6 9.1±5.2 1.4 0.522 0.694 
Laminin subunit beta-1  F1SAE9_PIG 3.6±2.6 7.6±1.7 2.1 0.060 0.301 
Laminin subunit beta-2  F1SPT5_PIG 9.4±2.0 10.5±3.3 1.1 0.630 0.778 
Laminin subunit gamma-1  F1S663_PIG 41.1±7.8 51.6±4.7 1.3 0.080 0.374 
Latent-TGFß-binding protein 1  F1S405_PIG 0.5±0.5 0.2±0.3 0.3 0.272 0.519 
Latent-TGFß-binding protein 2  F1S2T5_PIG 3.3±2.5 2.3±1.5 0.7 0.558 0.720 
Latent-TGFß-binding protein 4 LTBP4_PIG 1.0±1.9 2.9±0.9 3.1 n/a n/a 
Leukocyte elastase inhibitor  ILEU_PIG 1.3±1.7 0.0±0.0 0.0 n/a n/a 
Lipoprotein lipase* LIPL_PIG 1.4±1.0 0.0±0.0 0.0 n/a n/a 
Lumican  F1SQ09_PIG 201.5±83.1 274.7±84.1 1.4 0.310 0.548 
Lysyl oxidase homolog 1 F1SIC9_PIG 2.3±2.5 8.9±5.1 3.9 0.140 0.417 
Macrophage-capping protein  F1SVB0_PIG 0.0±0.0 0.1±0.1 n/a n/a n/a 
Matrix Gla protein  MGP_PIG 1.1±0.6 1.3±0.7 1.2 0.726 0.840 
Matrix-remodeling-associated 
protein5  
F1RZ07_PIG 5.8±7.9 2.3±3.1 0.4 0.467 0.649 
Mimecan  I3L9T6_PIG 222.1±65.9 359.4±47.8 1.6 0.024 0.288 
Myeloperoxidase  K7GRV6_PIG 5.0±5.4 0.0±0.0 0.0 n/a n/a 
Nidogen-1 NID1_PIG 1.3±0.3 2.2±0.6 1.7 0.095 0.384 
Nidogen-2  F1SFF3_PIG 107.0±40.5 191.0±42.9 1.8 0.055 0.301 
Papilin  F1S3J7_PIG 1.5±2.1 0.6±0.5 0.4 0.428 0.614 
Pentraxin-related protein PTX3* F1SJM0_PIG 1.6±0.5 0.0±0.0 0.0 n/a n/a 
Peptidyl-prolyl cis-trans 
isomerase A  
PPIA_PIG 3.5±2.1 3.2±0.8 0.9 0.780 0.879 
Periostin F1RS37_PIG 18.4±18.6 24.1±13.7 1.3 0.660 0.804 
Perlecan PGBM_PIG 223.6±75.7 314.7±59.1 1.4 0.134 0.413 
Peroxidasin homolog  I3LDA4_PIG 0.3±0.3 0.1±0.2 0.4 n/a n/a 
Pigment epithelium-derived 
factor  
Q0PM28_PIG 0.8±1.1 0.7±0.5 0.9 0.876 0.939 
Plasminogen  PLMN_PIG 28.7±24.0 0.4±0.6 0.0 0.099 0.384 
Podocan  I3LEB7_PIG 0.9±0.8 3.7±1.3 4.3 0.045 0.301 
Procollagen C-endopeptidase 
enchancer 1  
I3LEE6_PIG 0.4±0.5 0.9±0.7 2.3 0.373 0.565 
Prolargin  F1S6B4_PIG 203.8±44.9 319.0±81.4 1.6 0.117 0.403 
Prolow-density lipoprotein 
receptor-related protein 1  
K9IVL7_PIG 3.7±1.9 1.8±1.4 0.5 0.189 0.431 
Properdin  K7GQR1_PIG 0.7±0.6 0.1±0.1 0.2 0.152 0.420 
Prophenin and tritrpticin 
precursor  
PF11_PIG 116.0±100.2 0.3±0.5 0.0 n/a n/a 
Proteoglycan 4 I3L5Z3_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
RPE-spondin RPESP_PIG 6.6±1.5 7.6±0.6 1.2 0.274 0.519 
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Secreted frizzled-related protein 
1  
I3LB66_PIG 0.0±0.0 0.8±0.4 n/a n/a n/a 
Serine protease HTRA1  F1SEH4_PIG 5.9±3.4 24.5±17.8 4.2 0.208 0.463 
Serotransferrin  TRFE_PIG 3.3±3.0 0.2±0.3 0.1 n/a n/a 
Serum amyloid P-component  SAMP_PIG 0.2±0.3 0.0±0.0 0.0 n/a n/a 
SPARC  SPRC_PIG 1.4±1.6 3.1±0.6 2.2 0.122 0.403 
Spondin-1 SPON1_PIG 0.2±0.4 0.5±0.4 2.8 n/a n/a 
Sulfhydryl oxidase  F1S682_PIG 0.1±0.2 0.0±0.0 0.0 n/a n/a 
Superoxide dismutase [Cu-Zn]  Q007T6_PIG 0.9±1.0 3.2±1.9 3.4 0.156 0.420 
Target of Nesh-SH3* F1SL03_PIG 1.0±1.7 2.7±2.2 2.7 0.339 0.548 
Tenascin  TENA_PIG 81.9±36.9 36.0±30.0 0.4 0.131 0.413 
Tenascin XB*  A5A8W4_PIG 2.8±4.7 3.4±2.3 1.2 0.831 0.924 
Tetranectin  F1SRC8_PIG 1.1±1.0 1.4±0.7 1.2 0.698 0.818 
TGFß-1* TGFB1_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
TGFß-3* K7GSJ9_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
TGFß-induced protein ig-h3  BGH3_PIG 34.6±17.0 16.1±8.1 0.5 0.121 0.403 
Throbospondin-1 K7GPJ3_PIG 5.7±0.9 0.4±0.4 0.1 0.000 0.024 
Tryptase  TRYT_PIG 0.0±0.0 0.0±0.0 n/a n/a n/a 
Tubulointerstitial nephritis 
antigen-like  
F1SVA2_PIG 58.3±3.7 67.8±14.1 1.2 0.362 0.565 
Versican  F1REZ2_PIG 106.1±58.1 142.6±42.5 1.3 0.381 0.566 
Vitamin D-binding protein  I3LN42_PIG 7.3±7.7 0.5±0.5 0.1 0.173 0.429 
Vitronectin  VTNC_PIG 149.0±66.3 43.5±29.8 0.3 0.043 0.301 
von Willebrand factor A domain-
containing protein 1  
F1RJE3_PIG 11.1±2.7 16.8±5.1 1.5 0.183 0.431 
WD repeat-containing protein 1  K9IVR7_PIG 0.0±0.1 0.1±0.0 1.4 0.598 0.760 
 
P values for differential expression between BA early and BA late are based on unpaired Student’s t-tests with 
unequal variance (early: n=4 [day 1 + 3], late: n=3 [day 14 + 28]). T-test was not performed if a protein was 
undetectable in the majority of samples from 1 of the 2 groups compared. Results in bold indicate P < 0.05. 
Values are average (Av) total ion current (TIC) x 106 ± standard deviation (SD). n/a denotes not applicable, 
FC denotes fold change. FDR denotes false discovery rate. The FDR threshold was set at 10%. Protein 
changes with P <0.05 and a FDR of <10% are highlighted in bold. Proteins only identified in the media, but not 
neointima are marked with*. 
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Supplemental Table V. Significant extracellular protein changes between BMS or DES day 28 
vs. BA late. 
 
      BMS/BA      DES/BA   
Identified Proteins  UniProt ID 
MW 
(kDa) FC  P FDR   FC P FDR 
RPE-spondin RPESP_PIG 32 0.2 0.006 0.172  0.3 0.001 0.012 
Laminin subunit gamma-1  F1S663_PIG 177 0.9 0.562 0.697  0.3 0.001 0.012 
Galectin-3 A3EX84_PIG 27 23.4 0.395 0.612  6.8 0.002 0.012 
Collagen alpha-1 (XI)  F1S571_PIG 159 1.8 0.272 0.584  3.4 0.002 0.012 
Periostin F1RS37_PIG 93 6.1 0.394 0.612  11.9 0.002 0.012 
Biglycan  K7GP55_PIG 41 1.5 0.167 0.584  2.0 0.004 0.021 
Collagen alpha-1 (V)  F1S021_PIG 182 1.8 0.267 0.584  2.6 0.006 0.021 
Latent-TGFß-binding 
protein 2  F1S2T5_PIG 196 1.2 0.833 0.860  3.9 0.006 0.021 
Collagen alpha-1 (XVIII) COIA1_PIG 62 0.6 0.027 0.256  0.2 0.007 0.021 
Collagen alpha-1 (I) CO1A1_PIG 100 1.3 0.584 0.697  1.9 0.007 0.021 
Apolipoprotein H  I3LGN5_PIG 29 1.5 0.463 0.648  3.1 0.008 0.021 
Dermatopontin  DERM_PIG 22 1.7 0.328 0.599  2.0 0.008 0.021 
Collagen alpha-2 (I)  F1SFA7_PIG 129 1.2 0.639 0.734  2.0 0.010 0.024 
Laminin subunit beta-1  F1SAE9_PIG 199 1.2 0.197 0.584  0.3 0.013 0.028 
Fibronectin  F1SS24_PIG 272 1.6 0.243 0.584  2.9 0.014 0.028 
Aggrecan  F1SKR0_PIG 238 1.6 0.250 0.584  3.0 0.017 0.032 
Collagen alpha-1 (II)  I3LSV6_PIG 130 1.0 0.961 0.961  1.7 0.018 0.032 
Annexin A1  ANXA1_PIG 39 4.0 0.364 0.612  7.4 0.022 0.038 
Collagen alpha-2 (XI) A5D9K7_PIG 162 1.5 0.436 0.643  2.1 0.024 0.040 
Collagen alpha-1 (XII) COCA1_PIG 229 13.7 0.284 0.584  15.7 0.026 0.041 
Collagen alpha-1 (VIII)  F1SKX7_PIG 73 2.6 0.301 0.584  15.3 0.028 0.041 
Tetranectin  F1SRC8_PIG 22 1.7 0.118 0.523  4.9 0.036 0.049 
Gelsolin GELS_PIG 85 0.7 0.267 0.584  0.6 0.036 0.049 
Agrin  I3LGD9_PIG 216 0.9 0.693 0.740  0.6 0.040 0.050 
Nidogen-2  F1SFF3_PIG 152 0.9 0.687 0.740  0.5 0.042 0.050 
Galectin-1  LEG1_PIG 15 0.7 0.080 0.411  0.6 0.042 0.050 
Dystroglycan  I3LD20_PIG 95 0.3 0.046 0.285  0.4 0.043 0.050 
Podocan  I3LEB7_PIG 72 0.8 0.502 0.648  0.3 0.049 0.053 
Lactadherin  MFGM_PIG 46 1.6 0.498 0.648  0.5 0.050 0.053 
Throbospondin-1 K7GPJ3_PIG 120 6.5 0.031 0.256  14.8 0.090 0.093 
SPARC  SPRC_PIG 34 0.3 0.033 0.256  1.5 0.144 0.144 
 
P value and fold change (FC) for changes between BMS or DES day 28 and BA late are shown. P values are 
based on unpaired Student’s t-tests with unequal variance (n=3 [BMS day 28] or n=3 [DES day 28], n=3 [BA 
late]). T-test was not performed if a protein was undetectable in the majority of samples from 1 of the 2 groups 
compared. Results in bold indicate P < 0.05. FDR denotes false discovery rate. The FDR threshold was set at 
10%. 
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Supplemental Table VI. Differentially expressed proteins between DES and BMS at different time points. 
 
 
   Day 1  Day 3  Day 7  Day 28 
Identified Proteins UniProt ID 
MW 
(kDa) FC P FDR   FC P FDR   FC P FDR   FC P FDR 
Collagen alpha-2 (IV)  F1RLL9_PIG 161 0.6 0.362 0.683  0.6 0.338 0.676  1.2 0.707 0.868  0.3 <0.001 0.008 
Laminin subunit beta-1  F1SAE9_PIG 199 0.6 0.432 0.683  1.0 0.975 0.975  0.7 0.639 0.868  0.2 0.001 0.008 
Laminin subunit gamma-1  F1S663_PIG 177 0.9 0.741 0.803  1.1 0.440 0.770  1.1 0.753 0.868  0.3 0.011 0.050 
SPARC  SPRC_PIG 34 1.3 n/a n/a  0.1 0.036 0.201  0.9 0.802 0.868  5.6 0.014 0.050 
Hyaluronan and 
proteoglycan link protein 1  HPLN1_PIG 40 1.7 0.427 0.683  2.8 0.043 0.201  1.5 0.419 0.868  0.3 0.019 0.050 
Collagen alpha-1 (XVIII) COIA1_PIG 62 0.8 0.540 0.683  1.0 0.921 0.975  1.1 0.788 0.868  0.2 0.020 0.050 
Latent-TGFß-binding 
protein 2  F1S2T5_PIG 196 1.0 0.952 0.952  0.8 0.753 0.975  1.9 0.003 0.045  3.3 0.026 0.054 
Collagen alpha-1 (VIII)  F1SKX7_PIG 73 0.6 n/a n/a  2.0 n/a n/a  1.2 0.645 0.868  5.9 0.029 0.054 
Laminin subunit beta-2  F1SPT5_PIG 179 0.7 0.364 0.683  1.4 0.201 0.563  1.2 0.728 0.868  0.5 0.038 0.057 
Tubulointerstitial nephritis 
antigen-like  F1SVA2_PIG 52 0.9 0.326 0.683  1.2 0.686 0.975  1.3 0.125 0.625  0.7 0.038 0.057 
Aggrecan  F1SKR0_PIG 238 0.8 0.523 0.683  4.1 0.263 0.614  1.0 0.971 0.971  1.9 0.044 0.060 
TGFß-induced protein ig-h3  BGH3_PIG 74 0.5 0.045 0.293  1.0 0.950 0.975  2.4 0.368 0.868  0.3 0.206 0.258 
Prophenin and tritrpticin 
precursor  PF11_PIG 24 1.5 0.388 0.683  11.1 0.199 0.563  4.6 0.010 0.075  0.1 0.467 0.539 
Collagen alpha-1 (XII) COCA1_PIG 229 0.8 0.045 0.293  1.1 0.849 0.975  0.8 0.810 0.868  1.1 0.846 0.906 
Vitronectin  VTNC_PIG 53 0.7 0.578 0.683  2.9 0.019 0.201  1.6 0.440 0.868  0.9 0.947 0.947 
 
P values between DES and BMS at each time point are based on unpaired t-tests with unequal variance (n=3 [BMS day 1/3/7/28], n=3 [DES 1/3/7/28]). T-
test was not performed if a protein was undetectable in the majority of samples from 1 of the 2 groups compared. Only proteins with at least one significant 
result at any time point are shown. Results in bold indicate P < 0.05. n/a denotes not applicable, FC denotes fold change (DES/BMS). FDR denotes false 
discovery rate. The FDR threshold was set at 10%.  
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Supplemental Table VII. Transitions for targeted proteomics in human vessels. 
Protein Proteotypic peptide    + position 
Average 
RT (min) 
Precursor 
m/z  
Precursor 
z 
Fragment 
ion 
Fragment 
ion m/z 
Aggrecan C[+57]GGNLLGVR  45.0 473.2504 2 y3 331.21 
 C318 - R326    y4 444.29 
     y5 557.38 
     y6 671.42 
     y7 728.44 
          y8 785.46 
Versican LATVGELQAAWR 124.6 657.8619 2 y4 503.27 
 L277 - R288    y5 631.33 
     y6 744.42 
     y7 873.46 
     y8 930.48 
     y9 1029.55 
     y10 1130.60 
          y11 1201.63 
Decorin NLHALILVNNK 67.6 416.9189 3 y3 375.20 
 N106 - K116    y4 474.27 
     y5 587.35 
     y6 700.44 
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Supplemental Table VIII. Aortic extracellular proteins identified by proteomics analysis in 
mice lacking the catalytic domain of Adamts5 (Adamts5 Δcat) compared to controls. 
 
   WT 
Adamts5 
Δcat   
Identified Proteins  UniProt ID 
MW 
(kDa) 
Total ion current x 106 Av±SD P 
FC 
(Δcat 
/WT) 
Adipocyte enhancer-binding protein 
1  AEBP1_MOUSE 128 64.1±31.6 58.4±25.3 0.746 0.9 
Adiponectin  ADIPO_MOUSE 27 40.9±9.0 33.2±20.2 0.465 0.8 
Aggrecan PGCA_MOUSE 222 176.9±30.6 255.3±56.3 0.032 1.4 
Agrin  AGRIN_MOUSE 208 34.0±16.3 33.0±13.1 0.914 1.0 
Alpha-2-HS-glycoprotein  FETUA_MOUSE 37 11.8±14.4 15.4±14.3 0.689 1.3 
Amyloid beta A4 protein  A4_MOUSE 87 18.1±15.0 11.1±10.9 0.397 0.6 
Annexin A2  ANXA2_MOUSE 39 41.3±26.3 58.4±46.5 0.492 1.4 
Apolipoprotein A-I  APOA1_MOUSE 31 43.3±21.6 53.3±32.3 0.573 1.2 
Apolipoprotein A-IV  APOA4_MOUSE 45 21.6±13.2 26.7±7.4 0.450 1.2 
Apolipoprotein E  APOE_MOUSE 36 0.0±0.0 4.7±10.6 n/a n/a 
Asporin  ASPN_MOUSE 43 235.9±42.9 236.6±39.4 0.976 1.0 
Basal cell adhesion molecule  BCAM_MOUSE 68 180.7±43.3 185.7±33.6 0.835 1.0 
Basement membrane-specific 
heparan sulfate proteoglycan core 
protein  PGBM_MOUSE 398 2277.5±241.7 2497.0±107.5 0.085 1.1 
Beta-2-glycoprotein 1  APOH_MOUSE 39 54.3±19.6 64.0±16.8 0.400 1.2 
Biglycan  PGS1_MOUSE 42 2026.4±473.1 1924.8±417.8 0.714 0.9 
Cadherin-13  CAD13_MOUSE 78 24.6±12.0 30.7±10.3 0.388 1.2 
Cathepsin D  CATD_MOUSE 45 21.1±5.4 15.8±11.7 0.394 0.7 
Cell surface glycoprotein MUC18  MUC18_MOUSE 72 16.7±14.0 19.7±12.4 0.719 1.2 
Chondroitin sulfate proteoglycan 4  CSPG4_MOUSE 252 14.8±12.7 6.1±8.3 n/a 0.4 
Chymase  CMA1_MOUSE 28 76.0±27.3 79.1±27.5 0.854 1.0 
Clusterin  CLUS_MOUSE 52 80.6±14.8 93.2±31.9 0.450 1.2 
Collagen alpha-1 (I) CO1A1_MOUSE 138 17254.0±2798.8 21811.8±4876.9 0.113 1.3 
Collagen alpha-1 (II)   CO2A1_MOUSE 142 645.2±292.1 562.5±183.9 0.583 0.9 
Collagen alpha-1 (III) CO3A1_MOUSE 139 2265.9±1681.1 1177.9±635.7 0.189 0.5 
Collagen alpha-1 (IV) CO4A1_MOUSE 161 91.4±30.3 61.6±16.9 0.074 0.7 
Collagen alpha-1 (V)   CO5A1_MOUSE 184 281.7±52.1 290.4±66.5 0.817 1.0 
Collagen alpha-1 (VI)   CO6A1_MOUSE 108 213.0±64.7 209.5±106.6 0.951 1.0 
Collagen alpha-1 (XI)  COBA1_MOUSE 181 62.6±54.8 0.0±0.0 n/a 0.0 
Collagen alpha-1 (XIV)   COEA1_MOUSE 193 14.5±17.3 5.7±12.8 n/a 0.4 
Collagen alpha-1 (XV)   COFA1_MOUSE 140 137.4±35.4 151.9±42.4 0.560 1.1 
Collagen alpha-1 (XVIII)   COIA1_MOUSE 182 295.6±66.3 277.6±64.0 0.660 0.9 
Collagen alpha-2 (I)   CO1A2_MOUSE 130 11217.6±3451.6 11447.8±2260.1 0.897 1.0 
Collagen alpha-2 (IV)   CO4A2_MOUSE 167 36.9±26.3 53.8±31.3 0.367 1.5 
Collagen alpha-2 (V)   CO5A2_MOUSE 145 408.7±94.8 442.8±135.1 0.649 1.1 
Collagen alpha-2 (VI)   CO6A2_MOUSE 110 122.8±66.3 81.2±54.4 0.282 0.7 
Collagen alpha-2 (XI)   COBA2_MOUSE 172 7.5±18.3 0.0±0.0 n/a 0.0 
Collagen alpha-5 (VI)   CO6A5_MOUSE 290 5.7±13.8 0.0±0.0 n/a 0.0 
Collagen alpha-6 (VI)   CO6A6_MOUSE 246 81.1±50.5 91.9±86.1 0.812 1.1 
Connective tissue growth factor  CTGF_MOUSE 38 2.6±6.4 11.2±15.7 n/a 4.3 
Decorin  PGS2_MOUSE 40 1366.3±105.8 1401.5±270.2 0.795 1.0 
Dermatopontin  DERM_MOUSE 24 151.7±30.2 136.3±39.5 0.495 0.9 
Destrin  DEST_MOUSE 19 277.8±70.8 326.5±62.5 0.257 1.2 
Dystroglycan  DAG1_MOUSE 97 31.3±15.6 57.0±30.4 0.140 1.8 
Elastin  ELN_MOUSE 72 44.4±19.8 44.0±19.3 0.978 1.0 
EMILIN-1  EMIL1_MOUSE 108 4.2±10.3 0.0±0.0 n/a 0.0 
Extracellular superoxide dismutase 
[Cu-Zn]  SODE_MOUSE 27 430.7±126.7 416.8±106.0 0.847 1.0 
Fibrillin-1  FBN1_MOUSE 312 25.2±25.4 0.0±0.0 n/a 0.0 
Fibrinogen alpha chain  FIBA_MOUSE 87 38.7±26.0 23.2±27.0 0.360 0.6 
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Fibrinogen beta chain  FIBB_MOUSE 55 33.8±29.5 30.0±41.8 0.868 0.9 
Fibrinogen gamma chain  FIBG_MOUSE 49 60.0±56.4 40.0±34.1 0.487 0.7 
Fibromodulin  FMOD_MOUSE 43 9.6±7.6 6.9±7.4 0.578 0.7 
Fibronectin  FINC_MOUSE 273 1061.0±222.9 951.9±142.2 0.353 0.9 
Fibulin-5  FBLN5_MOUSE 50 62.2±27.6 73.3±23.2 0.487 1.2 
Galectin-1  LEG1_MOUSE 15 224.4±39.5 265.8±56.3 0.209 1.2 
Galectin-3  LEG3_MOUSE 28 14.3±7.3 30.5±29.9 0.297 2.1 
Hyaluronan and proteoglycan link 
protein 1  HPLN1_MOUSE 40 8.5±8.1 11.2±15.7 n/a 1.3 
Insulin-like growth factor-binding 
protein 7  IBP7_MOUSE 29 154.1±49.6 129.6±35.5 0.367 0.8 
Inter-alpha-trypsin inhibitor heavy 
chain H1  ITIH1_MOUSE 101 5.7±11.2 4.6±6.4 n/a 0.8 
Lactadherin  MFGM_MOUSE 51 384.5±33.4 387.7±63.6 0.923 1.0 
Laminin subunit alpha-2  LAMA2_MOUSE 344 1.8±4.4 0.0±0.0 n/a 0.0 
Laminin subunit alpha-4  LAMA4_MOUSE 202 43.6±8.6 37.0±25.6 0.611 0.9 
Laminin subunit alpha-5  LAMA5_MOUSE 404 48.3±13.5 35.5±20.4 0.272 0.7 
Laminin subunit beta-2  LAMB2_MOUSE 197 113.1±57.2 96.3±58.5 0.644 0.9 
Laminin subunit gamma-1  LAMC1_MOUSE 177 113.4±28.6 91.6±15.7 0.148 0.8 
Latent-TGFß-binding protein 1  LTBP1_MOUSE 187 47.3±15.7 50.1±13.6 0.756 1.1 
Latent-TGFß-binding protein 4  LTBP4_MOUSE 179 456.7±66.7 429.5±95.6 0.608 0.9 
Lumican  LUM_MOUSE 38 1799.7±751.8 1778.6±220.8 0.950 1.0 
Lysyl oxidase homolog 1  LOXL1_MOUSE 67 368.2±63.6 376.3±39.2 0.802 1.0 
Matrin-3  MATR3_MOUSE 95 1.4±3.4 0.0±0.0 n/a 0.0 
Microfibril-associated glycoprotein 4  MFAP4_MOUSE 29 101.6±32.5 127.7±31.3 0.210 1.3 
Microfibrillar-associated protein 5  MFAP5_MOUSE 19 66.0±70.8 88.8±90.0 0.658 1.3 
Mimecan MIME_MOUSE 34 1299.0±180.9 1605.9±194.2 0.026 1.2 
Nidogen-1  NID1_MOUSE 137 193.9±65.0 192.4±24.6 0.959 1.0 
Nidogen-2  NID2_MOUSE 154 123.2±35.4 109.1±36.4 0.533 0.9 
Periostin  POSTN_MOUSE 93 182.1±59.7 193.5±156.6 0.884 1.1 
Prolargin  PRELP_MOUSE 43 578.3±87.4 622.8±159.5 0.597 1.1 
Prosaposin  SAP_MOUSE 61 31.9±24.8 15.2±21.6 n/a 0.5 
Protein S100-A10  S10AA_MOUSE 11 15.8±24.4 0.0±0.0 n/a 0.0 
Protein S100-A11  S10AB_MOUSE 11 0.0±0.0 7.4±10.1 n/a n/a 
Secreted frizzled-related protein 1  SFRP1_MOUSE 35 1.0±2.5 0.0±0.0 n/a 0.0 
Serine protease HTRA1  HTRA1_MOUSE 51 169.9±40.2 197.7±38.0 0.270 1.2 
SPARC  SPRC_MOUSE 34 2.9±4.6 3.2±7.2 n/a 1.1 
Tenascin  TENA_MOUSE 232 6.2±9.7 1.8±4.0 n/a 0.3 
Tetranectin  TETN_MOUSE 22 0.0±0.0 2.4±5.3 n/a n/a 
TGFß-induced protein ig-h3  BGH3_MOUSE 75 24.2±16.2 9.8±17.5 n/a 0.4 
Thrombospondin type-1 domain-
containing protein 4  THSD4_MOUSE 113 44.1±26.6 64.0±21.0 0.198 1.5 
Versican CSPG2_MOUSE 367 254.8±25.0 240.0±36.3 0.467 0.9 
Vitamin D-binding protein  VTDB_MOUSE 54 0.0±0.0 3.5±7.8 n/a n/a 
Vitronectin VTNC_MOUSE 55 71.5±22.0 115.2±31.8 0.036 1.6 
 
P values for differential expression between aortas of wild type controls (WT) and mice lacking the catalytic 
domain of Adamts5 (Adamts5 Δcat) are based on unpaired Student’s t-tests with unequal variance (n=6 [WT] 
and n=5 [Adamts5 Δcat]). T-test was not performed if a protein was undetectable in the majority of samples from 
1 of the 2 groups compared. Results in bold indicate P < 0.05. Values are average (Av) total ion current (TIC) x 
106 ± standard deviation (SD). n/a denotes not applicable; FC denotes fold change. 
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Supplemental Table IX. Transitions for targeted proteomics in murine vessels. 
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SUPPLEMENTAL FIGURES 
Supplemental Figure I. Overview of proteomics comparisons. The following proteomics 
comparisons were conducted in porcine tissue: a) Stent dependent changes in the neointima. 
b) Changes in BMS/DES/BA at different time points. c) Comparison stent vs. BA at late stage. 
d) BMS/DES dependent changes at each time point.  
Supplemental Figure II. Reproducibility of LC-MS/MS. The neointima samples were run in 
duplicates by LC-MS/MS. The total spectral counts (R=0.998) and the sequence coverage 
(R=0.969) for each ECM protein correlated well between technical replicates. n=140 proteins 
x 14 samples (Pearson correlation). The Venn diagram displays the unique peptides identified 
either in both or only in the 1st and only in the 2nd analysis.  
Supplemental Figure III. Database search. The publically available porcine databases do 
not cover the entire sequence of each protein. In addition, not all proteins are well annotated 
in porcine databases. Thus, a custom-made database containing porcine sequences of 
previously published ECM proteins was generated. This figure shows the identification of total 
spectral counts for selected proteins using different databases: The application of a hybrid 
database, which is the combination of a pig and human database, is superior to a pig or human 
database alone for identifying and quantifying proteins analysed by LC-MS/MS due to a higher 
sequence match. For many ECM proteins, such as fibronectin and decorin, which are well 
annotated and fully sequenced, the custom-made database does not offer a major 
improvement. However, for other proteins, such as collagen alpha-1 (I) and perlecan, which 
are not well annotated or fully sequenced, the custom-made database has a remarkable 
impact on the sequence coverage and protein quantification.  
Supplemental Figure IV. Total identified proteins. Overall in the media and neointima a 
total of 151 unique ECM proteins were identified with a minimum of 2 high-confidence 
peptides. The Venn diagram depicts the findings in the media and neointima (114 common 
proteins, 11 only in the media, 26 only in the neointima).  
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Supplemental Figure V. Densitometry DES at different time points. Aggrecan NITEGE 
and versican DPEAAE neoepitopes generated by aggrecanase activity in DES at different 
time points. n=3 per time point. *P<0.05, **P<0.01, ***P<0.001 (1-way ANOVA [P<0.001] with 
Dunnett post hoc test to day 1). 
Supplemental Figure VI. Densitometry BMS vs DES day 28. Differences between BMS 
and DES at day 28. n=4 per group. **P<0.01 (t-test with unequal variance). 
Supplemental Figure VII. Aggrecan in human stented coronary artery. Co-localization of 
aggrecan (Alexa 633, displayed in green) and aggrecan NITEGE neoepitope (Alexa 568, 
displayed in red) in human stented coronary artery visualized by immunofluorescence. 
Overview image 20x, scale bar=500 µm; Zoomed-in areas 60x, scale bar=25 µm. 
Supplemental Figure VIII. Densitometry aggrecan in human vasculature. Protein 
abundance quantified by densitometry of immunoblots for the aggrecan NITEGE neoepitope, 
versican and decorin in human thoracic aortas and saphenous veins. n=4 per group. *P<0.05 
(t test with unequal variance).  
Supplemental Figure IX. Blood pressure measurements in mice. Systolic and diastolic 
blood pressure measurements. n=7 (WT), n=5 (Adamts5 Δcat), t-test with unequal variance. 
Supplemental Figure X. Cardiac output measurements in mice. Left ventricular ejection 
fraction (LVEF) as measured by CMR. n=5 (WT), n=7 (Adamts5 Δcat), t-test with unequal 
variance. 
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